Award Number: W81XWH-04-1-0569

TITLE: Stimulation of Estrogen Receptor Signaling in Breast Cancer by a Novel Chaperone Synuclein Gamma

PRINCIPAL INVESTIGATOR: Y. Eric Shi

CONTRACTING ORGANIZATION: North Shore University Hospital
Lake Success, NY 11042

REPORT DATE: June 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Stimulation of Estrogen Receptor Signaling in Breast Cancer by a Novel Chaperone Synuclein Gamma

Y. Eric Shi

E-Mail: Eshi@LIJ.EDU

North Shore University Hospital
Lake Success, NY 11042

The association between SNCG expression and the progression of steroid dependent cancers of breast and ovary promoted us to investigate the role of SNCG in regulation of ERα. SNCG strongly stimulated the ligand-dependent transcriptional activity of ERα in breast cancer cells. A notable finding relevant to this study is that SNCG, acting as a chaperone for ER, strongly stimulated the ligand-dependent transcriptional activity of ERα, ligand-dependent cell growth, and ligand-dependent mammary tumorigenesis. Augmentation of SNCG expression stimulated the transcriptional activity of ERα and ligand-dependent growth, whereas compromising endogenous SNCG expression suppressed ERα signaling and ligand-dependent growth.
Table of Contents

Introduction ..................................................................................................................4

Body ..........................................................................................................................4-10

Key Research Accomplishments and Reportable Outcomes.............................10

Conclusions ...............................................................................................................10-11

Appendices ...............................................................................................................3 papers
INTRODUCTION

SNCG was first identified and cloned in PI’s lab as a breast cancer specific gene, which is highly expressed in advanced infiltrating breast carcinomas but not in normal or benign breast tissue. Aberrant expression of SNCG was also associated with ovary cancer progression. Synucleins are a family of small proteins consisting of 3 known members, α synuclein (SNCA), β synuclein (SNCB), and γ synuclein (SNCG). Synucleins has been specifically implicated in neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). However, studies also indicated the potential role of synucleins particularly SNCG in the pathogenesis of steroid-responsive tumors of breast and ovary. What role SNCG has in breast and ovary and how it is implicated in breast and ovary cancer remains a mystery. The association between SNCG expression and the progression of steroid dependent cancers of breast and ovary promoted us to investigate the role of SNCG in regulation of estrogen receptor ER-α.

BODY

A notable finding relevant to this study is that SNCG strongly stimulated the ligand-dependent transcriptional activity of ER-α in breast cancer cells. Since SNCG binds to ER-α, Hsp70, and Hsp90 in the absence of ligand but does not bind to ER-α and Hsp90 following ligand binding, these data suggest that SNCG is not likely to function as a coactivator involved in the post ligand binding events (such as DNA binding); but rather functions as chaperone to maintain ER-α compatible for high affinity ligand binding. We hypotheses that: 1) one of the critical functions of SNCG on breast cancer pathogenesis is to stimulate ER-α transcriptional activity; and 2) SNCG stimulates ER-α activation by participating in Hsp-based multiprotein chaperone system for efficient activation of steroid receptors; and this stimulation of ER-α activation is mediated at the stage of hormone binding.

SA1. To determine the mechanism of SNCG-stimulated ER-α activation; particularly we will focus on Hsp-based multiprotein chaperone complex for ER-α and to determine whether the SNCG-stimulated hormone dependent ER-α transactivation is mediated at the stage of hormone binding (Finished. Cancer Res 63: 3899-3903, 2003; Cancer Res 64: 4539-4546, 2004).

SA1-1. SNCG strongly stimulated the ligand-dependent transcriptional activity of ERα in breast cancer cells (Cancer Res 63: 3899-3903, 2003). Augmentation of SNCG expression stimulated transcriptional activity of ERα, whereas compromising SNCG expression suppressed ERα signaling. The SNCG-stimulated EFα signaling was demonstrated in three different cell systems:

1. **Overexpression of SNCG stimulated transcriptional activity of ERα.** Transfection of SNCG gene into the SNCG-negative and ER-positive MCF-7 cells did not affect ERα expression but significantly stimulated E2-mediated activation of ERα. Overexpression of SNCG gene in MCF-7 cells increased E2-stimulated reporter activity 3.2-fold over the SNCG-negative control cells. The SNCG-stimulated transcriptional activity of ERα was ligand-dependent, because SNCG had no significant effect on the transcriptional activity of ERα in the absence of E2.

2. **Co-transfection of SNCG and ERα into SNCG-negative and ERα-negative MDA-MB-435 cells.** Treatment of ER-α-transfected MDA-MB-435 cells with E2 activated reporter activity, indicating the functional transcriptional activity of the transfected ERα gene. A significant stimulation of ERα signaling by SNCG was observed in MDA-MB-435 cells when the cells were co-transfected with ERα and SNCG constructs. SNCG increased ligand-dependent transcriptional activity 3.7-fold over the control cells.
3. **Antisense blocking SNCG expression in ERα-positive and SNCG-positive T47D cells.** The effect of SNCG expression on ERα transactivation was further demonstrated by inhibiting endogenous SNCG expression with SNCG antisense mRNA in T47D cells that express high levels of SNCG. Stable transfection of the SNCG antisense construct into T47D cells significantly reduced SNCG expression to 25% of that in control T47D cells. While E2 significantly stimulated the reporter activity in the control T47D cells, inhibition of SNCG expression reduced E2-responsive activity in two stable antisense-transfected T47D cell lines, AS-1 and AS-3 cells, to 21% and 13% of that in control T47D cells, respectively. Treatment of T47D cells with E2 resulted in a 25-fold increase over the non-treated cells. However, only 3.3- and 5.2-fold increase was observed in the AS-3 and AS-1 cells, respectively.

SA1.2. **Mechanisms by which SNCG stimulates ER signaling and ligand-dependent growth (Cancer Res 64: 4539-4546, 2004).** It is well documented that the activation of steroid receptors is modulated by a heterocomplex with several molecular chaperones, particularly with Hsp90 and Hsp70, which associate with the unliganded steroid receptors and maintain them in a high affinity hormone-binding conformation. The chaperone-like activity of synucleins has been demonstrated in the cell-free system. Because SNCG stimulated ligand-dependent transcriptional activity of ERα, which can be blocked by antiestrogen, we reason that SNCG may have a chaperone activity and participate in Hsp-based multiprotein chaperone complex for ERα.

SNCG is a novel Hsp70-associated chaperone, participated in the Hsp-based multiprotein chaperone complex for ERα. SNCG bound to the unliganded form of ER-α, Hsp90, and Hsp70. We investigated if SNCG can physically and functionally interact with ERα, Hsp70, and Hsp90 in SNCG transfected MCF-7 cells by co-immunoprecipitation assays. IP of ERα co-precipitated SNCG, Hsp70 and Hsp90 in the absence of estrogen (Fig. 1A) and vice versa (Fig. 1B), indicating that SNCG participated in a heterocomplex with Hsp90, Hsp70, and ER-α in the absence of estrogen. However, SNCG dissociated from ERα after the cells were treated with E2 (Fig. 1C). The binding pattern of SNCG to the unliganded ERα is same to that of Hsp90 and Hsp70, which only binds to the unliganded ER-α (34). Similar to its binding pattern to ERα, SNCG only bound to Hsp90 in the absence of estrogen (Fig. 1B). After cells were treated with E2, the liganded ER-α dissociated from SNCG, Hsp70, and Hsp90 (Fig. 1C). However, in contrast to its binding pattern to ERα and Hsp90, SNCG was found to bind to Hsp70 under the conditions both without (Fig. 1B) and with E2 (Fig. 1D), indicating that SNCG binds to Hsp70 constitutively regardless of whether Hsp70 is associated with ERα.

SNCG increases ligand binding by ERα. It has been proposed that Hsp-based chaperone complex inactivates the ER's transcriptional regulatory capabilities and maintains the ER in a conformation competent for steroid binding. We examined whether the SNCG-stimulated hormone dependent ERα transactivation results from increased estradiol binding by the receptor. As demonstrated in Fig. 2, SNCG significantly enhanced ligand-binding by ER. The biggest increases in the ligand binding were...
observed at the lower concentration range of 0.0025-1 nM of ligand. At the concentration of 1 nM of E2, the ligand binding was increased 160% in the SNCG-positive cells vs. the SNCG-negative control cells. Scatchard analysis revealed two binding sites (Fig. 3). The high affinity state was apparent in a linear plot between 0.0025nM and 1 nM of estradiol, and the low affinity state between 1 nM and 10 nM of estradiol. SNCG overexpression significantly enhanced the high affinity state of ER in MCF-7 cells, resulting in a 2.3-fold increase in high affinity binding capacity. While the high affinity binding capacity in MCF-7-neo cells was saturated when the bound E2 reached at 0.06 pmol/mg protein, the high affinity binding capacity in MCF-7-SNCG cells was saturated when the bound E2 reached at 0.14 pmol/mg protein. These data indicate that SNCG affects ER-α signal transduction pathway at the step of ligand binding by increasing the number of high affinity ligand-binding sites.

Fig. 2. Estrogen-binding capability for ER in SNCG-transfected MCF-7 cells (MCF-7-SNCG) and control neo-transfected cells (MCF-7-Neo). Cells were transiently transfected with pCI-SNCG or pCI-neo plasmids. The transfected cells were enriched with Neomycin selection for 12 days before the hormone binding assay. A, Western blot analysis of SNCG expression in pooled SNCG-transfected MCF-7 cells after selection with G418. B, Titration of 3H-E2 in MCF-7-Neo and MCF-7-SNCG cells. Inset, enlarged view of 3H-E2 titration from 0-1 nM of ligand.

Fig. 3. Scatchard analysis of the ligand-binding by ER from MCF-7-Neo cells (A) and MCF-7-SNCG cells (B). Unbroken line, high affinity sites; broken line, low affinity sites. C, The high affinity sites of MCF-7-Neo and MCF-7-SNCG cells. Specific binding was determined by subtracting the non-specific binding from samples incubated with 100-fold excess of non-labeled E2. Each data point is the mean ± SD of triplicate samples.

SA2. To study the biological relevance of SNCG-stimulated ER-α signaling to hormone-dependent tumorigenesis. The major goal of this specific aim is to determine if SNCG expression in breast cancer cells stimulate estrogen-mediated tumor growth. We will determine if expression of SNCG in breast cancer cells will stimulate estrogen-mediated tumor growth in nude mice. This will be investigated in

SA2-1. Stimulation of estrogen-mediated cell growth. The SNCG-stimulated ERα transcriptional activity is consistent with its stimulation of the ligand-dependent cell growth. It has been demonstrated in different systems that the interaction between SNCG and ERα stimulated cell growth.

MCF-7 cells. The cellular proliferation of two stably SNCG-transfected MCF-7 cell clones were compared with that of SNCG-negative neo clones. Fig 4A shows that while SNCG had no significant effect on the proliferation of SNCG-transfected cells compared to MCF-neo cells in the absence of E2, overexpression of SNCG significantly stimulated the ligand-dependent proliferation. Treatment of neo clones with E2 stimulated an average cell proliferation 2.4-fold over controls. However, E2 treatment of SNCG clones resulted in an average of 5.4-fold increase in the proliferation vs. controls, suggesting that SNCG expression renders the cells more responsive to E2-stimulated cell proliferation.

Fig. 4. SNCG stimulated ligand-dependent cell proliferation. For all experiments, cells were cultured and synchronized in the ligand-free Conditioned Cell Culture medium for 4 days before the hormone treatments. A, Stimulation of cell proliferation by SNCG overexpression. Cells were treated with or without 1 nM E2 for 24 hours. Cell proliferation was measured by 3H-thymidine incorporation. Data are means ± SD of three cultures. B, Effect of antiestrogens on SNCG-stimulated cell growth. Cells were treated with or without 1 nM of E2, 1 μM of tamoxifen, or 1 μM of ICI for 6 days before harvesting. Media were changed every two days with fresh estrogen and antiestrogens. Cell growth was measured using a cell proliferation kit (XTT). Data are the mean ± SD of quadruplicate cultures. Open bar represents MCF-neo1 cells; closed bar represents MCF-SNCG6 cells.

Blocking endogenous SNCG in T47D cells by antisense construct. Soft agar colony assays demonstrated that the anchorage-independent growth of T47D cells expressing SNCG antisense mRNA was significantly suppressed. When cells were cultured in soft agar without E2, there were very few colonies formed in both T47D group and T47D-SNCG antisense group. Treatment of T47D cells with E2 resulted in a 19-fold increase of colonies over the non-treated cells. However, treatment of T47D cells expressing SNCG antisense mRNA with E2 resulted in only 3-fold increase over the non-treated cells (Fig. 5). These data demonstrated that inhibition of endogenous SNCG expression dramatically diminished the cell growth in response to estrogen.
Fig. 5. Effect of inhibiting endogenous SNCG expression on soft agar colonies formation capability of T47D cells. T47D and SNCG antisense stably transfected AS-3 clone were cultured into the top layer soft agar and treated with or without 1 nM of E2 as described in Materials and Methods. The number of colonies was counted after 2 weeks of plating using a Nikon microscope at 100× amplification. Triplicate wells were assayed for each condition.

SA2-2. Stimulation of estrogen-dependent mammary tumorigenesis by SNCG (Cancer Res 64: 4539-4546, 2004). An orthotopic nude mouse model was used to study the effects of SNCG on tumor growth. Two independent experiments under different conditions were done to determine the effects of SNCG on mammary tumorigenesis.

We first analyzed the tumorigenesis in response to E2 in the non-ovariectomized intact mice. It was previously demonstrated that the circulating E2 level in the non-ovariectomized mice is 26 pg/ml (31), which compares to the low levels found in postmenopausal women (32). To override the endogenous levels of estrogen, all the mice were supplemented with E2 (0.72 mg/pellet) one day before injection of 5 x 10^6 cells. After a lag phase of 8-10 days, 29 of 32 (91%) injections in the mice given implants of SNCG positive MCF-SNCG2 and MCF-SNCG6 cells developed tumors. In contrast, only 21 of 32 (66%) injections in the mice given implants of SNCG negative MCF-neo1 and MCF-neo2 cells developed tumors (Table 1).

### Table 1. Effects of SNCG expression on tumor incidence and tumor growth of MCF-7 cells

<table>
<thead>
<tr>
<th>Experiment Group</th>
<th>E2</th>
<th>Tumor incidence</th>
<th>Tumor volume (mm³)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>tumor/total (%)</td>
<td>Day 21</td>
</tr>
<tr>
<td>MCF-SNCG2</td>
<td>+</td>
<td>14/16 (88)</td>
<td>234 ± 69</td>
</tr>
<tr>
<td>MCF-SNCG6</td>
<td>+</td>
<td>15/16 (94)</td>
<td>351 ± 78</td>
</tr>
<tr>
<td>MCF-neo1</td>
<td>+</td>
<td>10/16 (63)</td>
<td>101 ± 39</td>
</tr>
<tr>
<td>MCF-neo2</td>
<td>+</td>
<td>11/16 (69)</td>
<td>123 ± 25</td>
</tr>
</tbody>
</table>

Cells were injected into the mammary fat pads, and tumor volumes and tumor incidence were determined as described in Materials and Methods. Each mouse received two injections. Tumor volumes were measured at 21 days and 35 days following cell injection and are expressed as means ± SEs (number of tumors assayed). All the non-ovariectomized mice received an estrogen implantation one day before the cell injection. There were total 16 injections for 8 mice in each group, and each injection had 5 x 10^6 cells. Statistical comparisons for pooled SNCG positive clones relative to pooled SNCG negative clones indicated $P < 0.01$ for the mean tumor sizes and $P <0.05$ for the
tumor incidence. Statistical comparison for primary tumors was analyzed by Student's $t$ test. A chi-square test was used for statistical analysis of tumor incidence.

The tumor growths in MCF-SNCG clones were significantly stimulated. At 35 days following tumor cell injection, the size of MCF-SNCG6 tumors, which expressed relative high level of SNCG mRNA, was 4.8-fold of that in parental MCF-neo2 tumors and 3.7-fold of that in MCF-neo1 tumors. In addition, the tumor incidence was also increased. With 16 injections, while 15 implants in MCF-SNCG6 cells developed tumors, only 10 implants from MCF-neo1 and 11 implants from MCF-neo2 developed tumors, respectively. The tumor growth of MCF-SNCG2 cells was also significantly stimulated, with 3.5-fold and 2.7-fold increase in tumor size as compared to MCF-neo2 and MCF-neo1 tumors, respectively. **Fig. 6** shows growth kinetics. After a slow growth phase of 14 days, tumor growth of MCF-SNCG2 and MCF-SNCG6 clones were significantly enhanced as compared to that of MCF-neo1 and MCF-neo2 clones. Thus, the tumorigenesis of MCF-7 cells in response to E2 was significantly stimulated by the SNCG overexpression.

**Fig. 6.** Stimulation of MCF-7 tumor growth by SNCG. Each of the eight E2-supplemented non-ovariectomized mice in each group received two injections, one on each side, in the mammary fat pads between the first and second nipples. Tumor size was determined by three-dimensional measurements (mm) using a caliper. Only measurable tumors were used to calculate the mean tumor volume for each clone at each time point. Each point represents the mean of tumors ± SE (bars).

We then analyzed the requirement of E2 for SNCG-mediated tumor stimulation under more stringent conditions including use of ovariectomized mice and reduction of injected tumor cells from $5 \times 10^6$ to $1.5 \times 10^6$. As shown in **Table 2**, when the number of injected MCF-neo1 cells was reduced, the tumor incidence was greatly reduced from 63% to 0% both in the absence and presence of E2 supplement for up to 4 weeks, indicating a non-tumorigenic condition for SNCG-negative MCF-7 cells even with estrogen stimulation for 4 weeks. At the week 7, a 30% of tumor incidence with small tumor size (44 mm$^3$) was observed. However, for MCF-SNCG6 cells, although a same non-tumorigenic phenotype was observed under the conditions with reduced cell number and in the absence of E2, when E2 was supplemented, the tumor incidence reached to 90% at week 3 after cell inoculation, which is similar to 94% of tumor incidence in the experiment with higher injected cell numbers (**Table 1**). Furthermore, the tumor size of SNCG-positive cells is 4.4 fold over that of SNCG-negative cells. These data indicate that estrogen is necessary for SNCG-mediated tumor stimulation in the xenograft model.
Table 2. Stimulation of estrogen-mediated tumorigenesis by SNCG

<table>
<thead>
<tr>
<th>Group</th>
<th>E2</th>
<th>Tumor Incidence (%)</th>
<th>Tumor Vol (mm³)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Week 1 2 3 4 5 6 7</td>
<td>Week 7</td>
</tr>
<tr>
<td>MCF-neo1</td>
<td>-</td>
<td>0 0 0 0 0 0 0</td>
<td>0</td>
</tr>
<tr>
<td>MCF-neo1</td>
<td>+</td>
<td>0 0 0 0 20 30 30</td>
<td>44±10</td>
</tr>
<tr>
<td>MCF-SNCG6</td>
<td>-</td>
<td>0 0 0 0 0 0 0</td>
<td>0</td>
</tr>
<tr>
<td>MCF-SNCG6</td>
<td>+</td>
<td>40 80 90 90 90 90 90</td>
<td>194±35</td>
</tr>
</tbody>
</table>

Ovariectomized mice were treated with or without E2 pellet. There were total 10 injections for 5 mice in each group, and each injection had 1.5 x 10⁶ cells. Only measurable tumors were used to calculate the mean tumor volume. Statistical comparisons for SNCG positive clone relative to SNCG negative clone indicated $P < 0.001$ for both tumor incidence and mean tumor sizes in the presence of E2.

ADDITIONAL WORK (not proposed in the original grant)
Using transgenic mouse model, we demonstrated a role of SNCG in induction of highly proliferative pregnancy-like phenotype of mammary epithelial cells and branching morphology. SNCG participated in the heat shock protein-based multiprotein chaperone complex for steroid receptor signaling. Expression of SNCG in mammary epithelium resulted in a significant stimulation of ERα transcriptional activity. SNCG-induced mammary gland proliferation can be effectively blocked by antiestrogen and ovariectomy, indicating that the induced proliferation is mediated by ERα signaling and requires estrogen stimulation. These data indicate the chaperone activity of SNCG on stimulation of steroid receptor signaling in mammary gland and, thus induces extensive mammary gland proliferation and contributes to the hormonal impact on mammary tumorigenesis (Oncogene 26:2115-2125, 2007)

KEY RESEARCH ACCOMPLISHMENTS AND REPORTABLE OUTCOMES
1. SNCG strongly stimulated the ligand-dependent transcriptional activity of ERα in breast cancer cells. Augmentation of SNCG expression stimulated transcriptional activity of ERα, whereas compromising SNCG expression suppressed ERα signaling.
2. Stimulation of estrogen-mediated cell growth. The SNCG-stimulated ERα transcriptional activity is consistent with its stimulation of the ligand-dependent cell growth.
3. SNCG-mediated stimulation of ERα signaling and cell growth can be inhibited by antiestrogens.
4. Stimulation of estrogen-dependent mammary tumorigenesis by SNCG.
5. SNCG is a novel Hsp70-associated chaperone, participated in the Hsp-based multiprotein chaperone complex for ERα, and increased ligand binding by ERα.
6. Expression of SNCG in mammary epithelium results in a significant stimulation of ERα transcriptional activity and mammary gland proliferation

CONCLUSIONS
Although synucleins are emerging as central players in the formation of pathologically insoluble deposits characteristic of neurodegenerative diseases, γ Synuclein (SNCG), previously identified as a breast cancer specific gene (BCSG1), is also highly associated with breast or ovarian cancer.
progression. However, the molecular targets of SNCG aberrant expression for breast cancer have not been identified. Here we demonstrated a chaperone activity of SNCG in the heat shock protein-based multiprotein chaperone complex for stimulation of ER-α signaling. As an ER-α-associated chaperone, SNCG participated in Hsp-ER-α complex, enhanced the high affinity ligand-binding capacity of ER-α, and stimulated ligand-dependent activation of ER-α. The SNCG-mediated stimulation of ER-α transcriptional activity is consistent with its stimulation of mammary tumorigenesis in response to estrogen. These data indicate that SNCG is a new chaperone protein in the Hsp-based multiprotein chaperone complex for stimulation of ligand-dependent ER-α signaling and, thus, stimulates hormone responsive mammary tumorigenesis.
Stimulation of Estrogen Receptor Signaling by γ Synuclein

Yangfu Jiang, Yiliang Ellie Liu, AiPing Lu, Anu Gupta, Itzhak D. Goldberg, Jingwen Liu, and Y. Eric Shi

Department of Radiation Oncology, Long Island Jewish Medical Center, The Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New York 11040 [Y. J., Y. E. L., I. D. G., Y. E. S.], and Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304 [A. L., A. G., J. L.]

Abstract

Synucleins are emerging as central player in the fundamental neural processes and in the formation of pathologically insoluble deposits characteristic of Alzheimer’s disease and Parkinson’s disease. However, γ Synuclein (SNCG) is also highly associated with breast cancer and ovarian cancer progression. Whereas most studies of this group of proteins have been directed to the elucidation of their role in the formation of deposits in brain tissue, the normal cellular function of this highly conserved synuclein family remains largely unknown. A notable finding in this study is that SNCG, identified previously as a breast cancer-specific gene 1, strongly stimulated the ligand-dependent transcriptional activity of estrogen receptor-α (ER-α) in breast cancer cells. Augmentation of SNCG expression stimulated the transcriptional activity of ER-α, whereas compromising endogenous SNCG expression suppressed ER-α signaling. The SNCG-stimulated ER-α signaling was demonstrated in three different cell systems including ER-α-positive and SNCG-negative MCF-7 cells, ER-α-positive and SNCG-negative T47D cells, and SNCG-negative and ER-α-negative MDA-MB-435 cells. The SNCG-mediated stimulation of ER-α transcriptional activity is consistent with its stimulation of the ligand-dependent cell growth. Whereas overexpression of SNCG stimulated the ligand-dependent cell proliferation, suppression of endogenous SNCG expression significantly inhibited cell growth in response to estrogen. The stimulatory effect of SNCG on estrogen-regulated gene expression and cell growth can be effectively inhibited by antiestrogens. These data indicate that SNCG is required for efficient ER-α signaling and, thus, stimulated hormone-responsive mammary tumors.

Introduction

Synucleins are a family of small proteins consisting of 3 known members, SNCA, SNCB, and SNCG. Synucleins have been specifically implicated in neurodegenerative diseases such as AD and PD. Mutations in SNCA are genetically linked to several independent familial cases of PD (1). More importantly, wild-type SNCA is the major component of Lewy bodies in sporadic PD and in a subtype of AD known as Lewy body variant AD (2, 3). SNCA peptide known as nonamyloid component of plaques has been implicated in amyloidogenesis in AD (4, 5). SNCB and SNCG have also been recognized to play a role in the pathogenesis of PD and Lewy body cases (6, 7). Although synucleins are highly expressed in neuronal cells and are abundant in presynaptic terminals, synucleins have also been implicated in non-neural diseases, particularly in the hormone-responsive cancers of breast and ovary (8–13).

We have reported previously the isolation of differentially expressed genes in the cDNA libraries from normal breast and infiltrating breast cancer using differential cDNA sequencing approach (8, 14). Of many putative differentially expressed genes, a breast cancer-specific gene, BCSG1, was identified as a putative breast cancer-specific gene, which was highly expressed in a breast cancer cDNA library but scarcely in a normal breast cDNA library (8). Interestingly, BCSG1 revealed no homology to any other known growth factors or oncogenes; rather, BCSG1 revealed extensive sequence homology to neural protein synuclein, having 54% and 56% sequence identity with SNCA and SNCB, respectively. Subsequent to the isolation of BCSG1, synuclein γ (13) and persyn (15) were cloned independently from a brain genomic library and a brain cDNA library. In fact, BCSG1, SNCG, and persyn appear to be the same protein. Thus, the previously identified BCSG1, which is also highly expressed in brain, has been renamed as SNCG (16).

Although synucleins are abundant proteins expressed in presynaptic terminals and tightly associated with amyloid plaque in AD and Lewy body in PD, the normal cellular function of this highly conserved synuclein family remains largely unknown. Being identified as a breast cancer-specific gene, SNCG expression in breast follows a stage-specific manner: SNCG was undetectable in normal or benign breast lesions, showed partial expression in ductal carcinoma in situ, but expressed at an extremely high level in advanced infiltrating breast cancer (8, 11). Overexpression of SNCG in cancer cells led to significant increase in cell motility and invasiveness in vitro, profound augmentation of metastasis in vivo (9), and resistance to chemotherapeutic drug-induced apoptosis (17). Overexpression of synucleins, especially SNCG and SNCB, also correlated with ovarian cancer development (11, 13). Whereas synuclein (α, β, and γ) expression was not detectable in normal ovarian epithelium, 87% (39 of 45) of ovarian carcinomas were found to express either SNCG or SNCB, and 42% (19 of 45) expressed all three of the synucleins (α, β, and γ) simultaneously (11). The involvement of SNCG in hormone-responsive cancers of breast and ovary prompted us to explore the potential role of SNCG in cellular response to estrogen. In the present study, we evaluated the biological functions of SNCG on regulation of estrogen-receptor transcriptional activity in human breast cancer cells. The results suggest that one of the critical functions of SNCG on breast cancer pathogenesis is to stimulate ER-α transcriptional activity.

Materials and Methods

Conditioned Cell Culture. All of the cell lines used in this study (MCF-7, T47-D, and MDA-MB-435) were originally obtained from the American Type Culture Collection. Proliferating subconfluent human breast cancer cells were harvested and cultured in the phenol red-free IMEM containing 5% charcoal-stripped FCS for 4 days before addition of indicated dose of E2. Cells in the absence or presence of E2 were collected 24 h after addition of E2 and were subjected to the assays for ER-α transcriptional activity.

Received 11/19/02; accepted 6/2/03.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported in part by Grant 99-028-04-CCE from American Cancer Society, Grants DAMD17-98-1-8118 and DAMD17-01-1-0352 from the United States Army Medical Research and Development Command, Grant from the Department of Veterans Affairs (Office of Research and Development, Medical Research Service), and by Grant 1RO1CA83648-01 from National Cancer Institute.

2 To whom requests for reprints should be addressed, at Department of Radiation Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040. Phone: (718) 470-3086; Fax: (718) 470-9756; E-mail: shi@lij.edu.

3 The abbreviations used are: SNCA, α-synuclein; AD, Alzheimer’s disease; BCSG1, breast cancer specific gene 1; ER, estrogen receptor; Cat-D, cathepsin D; Hsp, heat shock protein; PD, Parkinson’s disease; PR, progesterone receptor; SNCG, SNCG, SNCB, SNCA, ERE, estrogen response element; RT-PCR, reverse transcription-PCR; E2, 17β-estradiol; TGF, transforming growth factor; ERE4-Luc, ERE4-Luciferase; ICI, ICI 182,780.
Gene Transfection. Subconfluent proliferating cells in 12-well plate were incubated with 2 μg of expression vectors in 1 ml of serum-free IMEM containing LipofectAMINE for 5 h. Culture was washed to remove the excess vector and LipofectAMINE, and then postincubated for 24 h in fresh culture medium to allow the expression of transfected gene.

Assays for the Transcriptional Activity of ER-α. Cells were transiently transfected with a firefly luciferase reporter construct (pERE4-Luc) containing four copies of the ERE (18). For the cotransfection experiments, the plasmid DNA ratio of pERE4Luc to expression vectors of ER-α or SNCG was 2:1. A renilla luciferase reporter, pRL-SV40-Luc, was used as an internal control for transfection efficiency. Luciferase activities in total cell lysate were measured using the Promega Dual Luciferase Assay System. Absolute ERE promoter firefly luciferase activity was normalized against renilla luciferase activity to correct for transfection efficiency. Triplicate wells were assayed for each transfection condition, and at least three independent transfection assays were performed.

RT-PCR Analysis. MCF-7-derived cells were cultured in ligand-free medium for at least 5 days, and treated with 10^{-9} M E_2 for 4 h as indicated. Total RNA from cells was isolated using RNasea Kit (Qiagen Inc.). Approximately 4 μg of total RNA was subjected to semi-quantitative RT-PCR analysis following a procedure described previously for estrogen-responsive genes (19, 20). The primer sequences (5'-3') are as follows: TGF-α, sense CGGCCCTGT-TGCTCTGGGTAT, antisense AAGGAGTGGCAGTGTACCA (240 bp product); cathepsin-D, sense CCAGGCCCCAATCCCAACCCCACCTCC, antisense ACTGAAAGTGGGAGGCTAAGCG (842-bp product); and PS2, sense CATGGAGAACAGGTGATCTG, antisense CAGAAGGCTGTGAGGGTGTC (336-bp product).

Stable Expression of SNCG Antisense mRNA in T47D Cells. A 285-bp DNA fragment corresponding to the exon 1 region (~169 to +116) of SNCG gene was amplified from the plasmid pBS-SNCG759 and was cloned into the EcoRI site of the expression vector pCDNA3.1. The antisense or sense orientation of the exon 1 in the pcDNA3.1 vector was determined by restriction enzyme digestion and was verified by DNA sequencing. Vectors expressing SNCG antisense mRNA (pcDNA-SNCG-As) or SNCG sense mRNA (pcDNA-SNCG-S) were transfected separately into T47D cells by Effectin reagent. Isolated clones were picked up after G418 selection. The expression of SNCG antisense and sense mRNAs (285 bp) in the individual clones was confirmed by RT-PCR reaction. For antisense mRNA, the primer sets are: T7 as the forward primer, 5' TAATACGACTCACTATAGGG 3' and SNCG-Wf as the reverse primer, ACGCAGGGCTGGCTGGGCCCTCA. The primer sets for detection of sense mRNA are: T7 as the forward primer, 5' TAATACGACCTACTATAGGG 3' and SNCG-Wr as the reverse primer, 5' CTTGCT-TGTTCTTTCACC 3'.

Cell Proliferation Assay. For [3H]thymidine incorporation, cells were cultured and synchronized in the conditioned medium for 4 days as described in “Conditioned Cell Culture.” Cells were treated with or without 1 nM of E_2 for 24 h. [3H]Thymidine was added 12 h before harvesting. [3H]Thymidine incorporation was determined by precipitation with 10% trichloroacetic acid followed by liquid scintillation counting. Triplicate wells were assayed for each cellular proliferation condition, and at least three independent assays were performed. Cell growth was also measured using a cell proliferation kit (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt; Roche Molecular Biochemicals, Indianapolis, IN). Briefly, exponentially growing cells were seeded in quadruplicate at 1500 cells per well (96-well plate) in the conditioned medium. Cells were treated with indicated chemicals for 6 days before harvesting.

Soft Agar Colony Formation Assay. The anchorage-independent growth was carried out in 12-well plates as we described previously (10). The bottom layer consists of 0.5 ml of 5% charcoal-stripped calf serum/IMEM containing 0.6% agar. The top layer consists of 0.25 ml of 5% charcoal-stripped calf serum/IMEM containing 0.4% agar and ~2000 cells. In the E_2-treated groups, the top layer also contains 1 nM of E_2. Cells were cultured under high humidity condition. Cells were fed with 0.1 ml of culture medium with or without E_2 every 4 days. After 2 weeks, the number of colonies in each well was counted under a Nikon microscope at ×100 amplification. Triplicate wells were assayed for each condition.

Results

Overexpression of SNCG Stimulated Transcriptional Activity of ER-α. Estrogen response is mediated by two closely related members of the nuclear receptor family of transcription factors, ER-α and ER-β (21, 22). Because ER-α is the major ER in mammary epithelia, we measured the effect of SNCG on modulating the transcriptional activity of ER-α in human breast cancer cells. We first selected ERe-positive and SNCG-negative MCF-7 cells as recipients for SNCG transfection (Fig. 1, A and B). MCF-7 cells were transiently transfected with either the pcI-SNCG expression plasmid or control pcI-neo plasmid. Transfection of the SNCG gene into the SNCG-negative MCF-7 cells did not affect ER-α expression under the conditions both with and without E_2 (Fig. 1A). In the absence of E_2, the basal levels of ER-α on control and SNCG-transfected cells are the same. Although treatment of the control cells with E_2 resulted in a significant decrease in ER-α level, overexpression of SNCG did not affect E_2-mediated degradation of ER-α. Transfection of SNCG significantly stimulated E_2-mediated activation of ER-α (Fig. 1B). Treatment of wild-type and SNCG-transfected MCF-7 cells with E_2 resulted in a significantly differential increase in estrogen-responsive reporter ERE4-Luc activity relative to basal levels in untreated cells. Overexpression of the SNCG gene in MCF-7 cells increased E_2-stimulated reporter activity 3.2-fold over the SNCG-negative control cells. The SNCG-stimulated transcriptional activity of ER-α was ligand-dependent, because SNCG had no significant effect on the transcriptional activity of ER-α in the absence of E_2.

Consistent with the increased transcriptional activity of ER-α,
SNCG also stimulated E₂-regulated genes in MCF-7 cells (Fig. 2). Whereas SNCG had no effect on the transcription of Cat-D, PS2, and TGF-α in the absence of E₂, transcription of Cat-D, PS2, and TGF-α were increased 3.9-fold, 3.2-fold, and 4.2-fold in SNCG transfected cells versus control cells in the presence of E₂, respectively (Fig. 2A). To evaluate the effect of antiestrogen on SNCG-stimulated ER-α-regulated genes, we treated the cells with an antiestrogen ICI. As demonstrated in Fig. 2B, the basal levels of PR were very weak in both SNCG-transfected and control cells, but were increased significantly by E₂ treatment. Treatment of the cells with E₂ stimulated a 3.5-fold PR protein expression in SNCG-transfected cells compared with control cells. Although ICI slightly stimulated basal levels of PR, treatment of the SNCG-transfected MCF-7 cells with ICI significantly blocked E₂-stimulated PR expression, indicating that SNCG-stimulated gene expression in E₂-treated cells is mediated by ER-α.

We also investigated the effect of SNCG on the transcriptional activity of ER-α in ER-α-negative and SNCG-negative MDA-MB-435 breast cancer cells (Fig. 3). Treatment of ER-α-transfected MDA-MB-435 cells with E₂ activated reporter activity, indicating the functional transcriptional activity of the transfected ER-α gene. A significant stimulation of ER-α signaling by SNCG was observed in MDA-MB-435 cells when the cells were cotransfected with ER-α and SNCG constructs. SNCG increased ligand-dependent transcriptional activity 3.7-fold over the control cells.

Reduced Levels of SNCG Promised Transcriptional Activity of ER-α. The effect of SNCG expression on ER-α transactivation was additionally demonstrated by inhibiting endogenous SNCG expression with SNCG antisense mRNA in T47D cells that express high levels of SNCG (8). Stable transfection of the SNCG antisense construct into T47D cells significantly reduced SNCG expression to 25% of that in control T47D cells (Fig. 4A). Whereas E₂ significantly stimulated the reporter activity in the control T47D cells, inhibition of SNCG expression reduced E₂-responsive luciferase activity in two stable antisense-transfected T47D cell lines, AS-1 and AS-3 cells, to 21% and 13% of that in control T47D cells, respectively (Fig. 4B). Treatment of T47D cells with E₂ resulted in a 25-fold increase over the nontreated cells. However, only 3.3- and 5.2-fold increase was observed in the AS-3 and AS-1 cells, respectively. Taken together, the increased estrogen-responsive reporter activity in SNCG-transfected MCF-7 and MDA-MB-435 cells, as well as the increased estrogen-regulated gene transcription and the compromised transcriptional activity of ER-α in SNCG antisense-transfected T47D cells indicated that SNCG stimulated ligand-dependent transcriptional activity of ER-α.

Stimulation of Cell Proliferation by SNCG. To determine the biological relevance of SNCG-stimulated ligand-dependent ER-α signaling, we analyzed the effect of SNCG overexpression on the growth of breast cancer cells. To determine whether SNCG overexpression affects ligand-dependent or ligand-independent cell growth, the cellular proliferation of the previously established two stable SNCG-transfected MCF-7 cell clones, MCF-SNCG2 and MCF-SNCG6, were compared with that of SNCG-negative cells, MCF-neo1 and MCF-neo2 (10). Data in Fig. 5A shows that whereas SNCG had no signif-
The effect of SNCG expression on cell growth was also demonstrated in the SNCG antisense construct-transfected T47D cells. SNCG antisense mRNA expression reduced SNCG protein expression to the level of 25% of that in control T47D cells (Fig. 4A). Soft agar colony assays demonstrated that the anchorag-independent growth of T47D cells expressing SNCG antisense mRNA was suppressed significantly. When cells were cultured in soft agar without E2, there were very few colonies formed in both the T47D group and T47D-SNCG antisense group. Treatment of T47D cells with E2 resulted in a 19-fold increase of colonies over the nontreated cells. However, treatment of T47D cells expressing SNCG antisense mRNA with E2 resulted in only 3-fold increase over the nontreated cells (Fig. 6). These data demonstrated that inhibition of endogenous SNCG expression dramatically diminished the cell growth in response to estrogen. Consistent with its stimulatory effect on ligand-dependent cell proliferation, overexpression of SNCG did not affect the proliferation of ER-α-negative MDA-MB-435 cells (9).

**Discussion**

Synucleins are small proteins expressed predominately in neurons, and have been specifically implicated in the neurodegenerative disorders such as AD and PD. Most studies of this group of proteins have been directed to the elucidation of their role in the formation of depositions in brain tissue. However, studies also indicated the potential role of synucleins, particularly SNCG, in the pathogenesis of steroid-responsive tumors of breast and ovary. SNCG was first identified and cloned as a breast cancer-specific gene, which is highly expressed in advanced infiltrating breast carcinomas but not in normal or benign breast tissues (8). Aberrant expression of SNCG was also associated with ovary cancer progression (11). What role SNCG has in breast and ovary, and how it is implicated in breast and ovary cancer remains a mystery. The association between SNCG expression and the progression of steroid-dependent cancers of breast and ovary led us to investigate the role of SNCG in the regulation of ER-α. Here we reported that SNCG strongly stimulated the ligand-dependent transcriptional activity of ER-α. Whereas SNCG overexpression stimulated transcriptional activity of ER-α, compromising SNCG expression suppressed ER-α signaling. The SNCG-stimulated ER-α signaling was demonstrated in three different cell systems including: (a) overexpression of SNCG in ER-α-positive and SNCG-negative MCF-7 cells; (b) antisense blocking SNCG expression in ER-α-positive and SNCG-positive T47D cells; and (c) cotransfection of SNCG and ER-α into SNCG-negative and ER-α-negative MDA-MB-435 cells. The results shown in this report demonstrated that human ER-α requires SNCG for efficient transcriptional activity.

The SNCG-mediated stimulation of ER-α transcriptional activity is consistent with its stimulation of the ligand-dependent cell growth. It has been demonstrated in different systems that the interaction between SNCG and ER-α stimulated cell growth. First, whereas expression of SNCG in MCF-7 cells had no effect on the cell growth in the absence of E2, SNCG significantly stimulated the ligand-dependent cell growth, which can be blocked by antiestrogens. This growth stimulation was also demonstrated previously in the anchorage-independent growth assay (10). Second, when endogenous SNCG expression in T47D cells was blocked by expressing SNCG antisense mRNA, the anchorage-independent growth in response to E2 was significantly suppressed in the cells expressing antisense SNCG. Third, although the alternation of SNCG expression affected the cell growth of ER-α-positive MCF-7 and T47D cells, it had no effect on the cell growth of ER-α-negative MDA-MB-435 cells (9). Consistent with the requirement of E2 for SNCG-stimulated cell growth, we also demonstrated previously that SNCG has no significant effect on tumor growth of ER-α-negative MDA-MB-435 cells (9).
To acquire the ability to bind hormone, steroid hormone receptors undergo a series of transformation steps in which they are brought into the correct conformation by molecular chaperones and co-chaperones. The most extensively studied chaperones for steroid receptors are a multigene family of Hsp90- and Hsp90-based chaperone system, which includes Hsp90, Hsp70, Hsp40, and p23 (21-23). Hsp70 and Hsp90 associate with the unliganded steroid hormone receptors, and maintain the conformational state for efficient ligand binding and receptor activation (21, 23). Interestingly, the chaperone-like activity has been suggested for synucleins based on the cell-free system (24). However, the molecular targets for synuclein-mediated chaperone activity remain to be identified. It is likely that SNCG is a new member of molecular chaperone proteins that participate in Hsp-based chaperone complex for regulating ER-α activity. Studies are under way to investigate the mechanism by which SNCG regulates ER-α signaling.

Like SNCA of which the mutations have been detected in several cases of familial PD (1), mutations of SNCG could be linked to the development of breast carcinomas. However, after analysis of a number of breast tumors and breast cancer cell lines, it was found that the malignant phenotype correlated with the high level expression of wild-type SNCG protein (8, 11, 15). Moreover, in addition to the absence of mutation, SNCG gene amplification was also not detected in breast tumors (15). To elucidate the molecular mechanisms underlying the abnormal transcription of SNCG in breast cancer cells, we isolated a 2195-bp promoter fragment of human SNCG gene and demonstrated that demethylation of exon 1 region of SNCG gene is an important factor responsible for the aberrant expression of SNCG in breast carcinomas (12). However, the molecular targets of SNCG aberrant expression for breast cancer have not been identified. Here we demonstrated ER-α as one of the critical target molecules for the action of SNCG in breast cancer pathogenesis. Thus, aberrant expression of SNCG stimulates breast cancer growth and progression, at least in part, by enhancing the transcriptional activity of ER-α. The role of SNCG in breast cancer progression may also be involved in non-ER-mediated functions such as stimulation of tumor motility and metastasis as we described previously in hormone-independent breast cancer cells (9).

The preventive effect of estrogen on AD has become clear with epidemiological data, suggesting that estrogen may act as a neuroprotectant against the neurodegenerative diseases (25-28). The cellular functions of synucleins remain elusive. The demonstration of ER-α as the critical target for SNCG may indicate a new direction of normal cellular function of synucleins. In this regard, SNCG-mediated stimulation of ER-α signaling not only supports its pathological role in the growth of steroid-responsive tumors, but may also shed some light on the cellular functions of synucleins in brain cells and their complex roles in the development of neurodegenerative disorders. References

Synuclein, a Novel Heat-Shock Protein-Associated Chaperone, Stimulates Ligand-Dependent Estrogen Receptor α Signaling and Mammary Tumorigenesis

Yangfu Jiang, Yiliang Ellie Liu, Itzhak D. Goldberg, and Y. Eric Shi

ABSTRACT

Synucleins are emerging as central players in the formation of pathologically insoluble deposits characteristic of neurodegenerative diseases. γ synuclein (SNCG), previously identified as a breast-cancer-specific gene (BCSG1), is also highly associated with breast or ovarian cancer progression. However, the molecular targets of SNCG aberrant expression in breast cancer have not been identified. Here, we demonstrated a chaperone activity of SNCG in the heat-shock protein (Hsp)-based multiprotein chaperone complex for stimulation of estrogen receptor (ER-α) signaling. As an ER-α-associated chaperone, SNCG participated in Hsp-ER-α complex, enhanced the high-affinity ligand-binding capacity of ER-α, and stimulated ligand-dependent activation of ER-α. The SNCG-mediated stimulation of ER-α transcriptional activity is consistent with its stimulation of mammary tumorigenesis in response to estrogen. These data indicate that SNCG is a new chaperone protein in the Hsp-based multiprotein chaperone complex for stimulation of ligand-dependent ER-α signaling and thus stimulates hormone-responsive mammary tumorigenesis.

INTRODUCTION

Using the differential cDNA sequencing (1–3), we undertook a search for differentially expressed genes in the cDNA libraries from normal breast and breast carcinoma. Of many putative differentially expressed genes, a breast cancer-specific gene, BCSG1, was identified as a putative breast cancer marker (1). This gene was highly expressed in the advanced breast cancer cDNA library but scarce in a normal breast cDNA library. BCSG1 is not homologous to any other known growth factors or oncoproteins. Rather, there is extensive sequence homology to the neural protein synuclein. Subsequent to the isolation of BCSG1, γ synuclein (SNCG; Ref. 4) and persyn (5) were independently cloned from a brain genomic library and a brain cDNA library. The sequences of these two brain proteins were found to be identical to BCSG1. Thus, the previously identified BCSG1 has also been named as SNCG and is considered to be the third member of the synuclein family (6).

Synucleins are a family of small proteins consisting of 3 known members, α synuclein (SNCA), β synuclein (SNCB), and γ synuclein (SNCG). Synucleins have been specifically implicated in neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Mutations in SNCA are genetically linked to several independent familial cases of PD (7). More importantly, wild type of SNCA is the major component of Lewy bodies in sporadic PD and in a subtype of AD known as Lewy body variant AD (8, 9). SNCA peptide known as nonamyloid component of plaques has been implicated in amyloidogenesis in AD (10, 11). SNCB and SNCG have also been implicated in amyloidogenesis in AD (10, 11). SNCB and SNCG have also been implicated in nonneural diseases, particularly in the neuronal cells and are abundant in presynaptic terminals, they have also been implicated in nonneural diseases, particularly in the hormone-responsive cancers of breast and ovary (1, 4, 14–22).

Being identified as a breast cancer-specific gene, SNCG expression in breast follows a stage-specific manner (1). Overall SNCG mRNA expression was detectable in 39% of breast cancers. However, 79% of stage III/IV breast cancers were positive for SNCG expression, whereas only 15% of stage I/II breast cancers were positive for SNCG expression. In contrast, the expression of SNCG was undetectable in all benign breast lesions (17). The expression of SNCG was strongly correlated with the stage of breast cancer. Overexpression of SNCG in breast cancer cells led to a significant increase in cell motility and invasiveness in vitro and a profound augmentation of metastasis in vivo (14). Overexpression of synucleins, especially SNCG and SNCB, also correlated with ovarian cancer development (4, 19). Although synucleins’ (α, β, and γ) expression was not detectable in normal ovarian epithelium, 87% (39 of 45) of ovarian carcinomas were found to express either SNCG or SNCB, and 42% (19 of 45) expressed all three synucleins (α, β, and γ) simultaneously (19). The involvement of SNCG in hormone-responsive cancers of breast and ovary promoted us to explore the potential role of SNCG in cellular response to estrogen. Previously, we investigated the functions of SNCG in regulating estrogen receptor transcriptional activity and demonstrated that SNCG strongly stimulated the ligand-dependent transcriptional activity of estrogen receptor (ER-α) in breast cancer cells. Augmentation of SNCG expression stimulated the transcriptional activity of ER-α, whereas compromising endogenous SNCG expression suppressed ER-α signaling (16). In the present study, we evaluated the mechanism by which SNCG stimulated ER-α transcriptional activity and its biological relevance to estrogen-stimulated mammary tumorigenesis. The results indicated that SNCG stimulates ER-α signaling by acting as a chaperone in the heat-shock protein (Hsp)-based multiprotein chaperone complex of ER-α and enhances its high-affinity ligand binding.

MATERIALS AND METHODS

Reagents. Improved MEM, FCS, and charcoal-stripped FCS were obtained from Biosource International (Camarillo, CA). 17-β-Estradiol (E2) and geldanamycin (GA) were purchased from Sigma Chemical Co. (St. Louis, MO). [3H]Estradiol was from Perkin-Elmer Life Science, Inc. (Boston, MA). The mammalian expression plasmid pCI-neo was from Promega (Madison, WI).

Cell Culture. All cell lines used in this study (MCF-7, T47-D) were originally obtained from the American Type Culture Collection. Proliferating confluent human breast cancer cells were harvested and cultured in the phenol red-free improved MEM containing 5% charcoal-stripped FCS for 4 days before addition of indicated dose of E2. Cells in the absence or presence of E2 were collected for ligand-binding assay or immunoprecipitation/Western blot analyses.

Gene Transfection. Subconfluent cells in 12-well plate were incubated with 2 μg of expression vectors in 1 ml of serum-free improved MEM containing LipofectAMINE (Life Technologies, Inc., Gaithersburg, MD) for 5 h. Culture was washed to remove the excess vector and LipofectAMINE and then postincubated for 24 h in fresh culture medium to allow the expression of transfected gene. For stable transfection, transfected cells were routinely

Received 11/21/03; revised 1/26/04; accepted 4/11/04.

Grant support: American Cancer Society Grant 99-028-01-CCE and United States Army Medical Research and Development Command Grants DAMD17-98-1-8118 and DAMD17-01-1-0352.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Y. Eric Shi, Department of Radiation Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040. Phone: (718) 470-3086; Fax: (718) 470-9756; E-mail: shi@ljmed.edu.
selected with G418 (600 μg/ml). Individual colonies were picked to establish stable clones.

**Immunoprecipitation.** Cells were cultured in 100-mm cell culture dishes in ligand-free medium for 4 days as described in “Cell Culture.” Cells were treated with or without E2 for 3 days before the total cell lysates were prepared. Cells were lysed in solution containing 1 × PBS, 1% Triton X-100, 10 mM sodium molybdate, 2 mg/ml aprotinin, 0.5 mg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Cells then were disrupted by sonication and centrifuged for 10 min at 10,000 × g. The protein concentrations of the supernatant were determined by BCA Protein Assay kit (Pierce). Cells lysates (1 mg of total cellular protein) were incubated with 2 μg of indicated antibody at room temperature for 1.5 h followed by the addition of protein G-Sepharose. The beads were washed four times with the lysis buffer described above, and the bound proteins were eluted with 1 × SDS gel-loading buffer followed by Western blotting.

**Western Blot Analysis.** Proteins were fractionated by electrophoresis through a SDS polyacrylamide gel, and the proteins were then transferred onto a nitrocellulose membrane. The membrane was blocked for 2 h in blocking buffer and then incubated with primary antibodies at room temperature for 2 h. After washing with Tris-buffered saline/0.2% Tween 20 buffer, the membrane was incubated with secondary antibody conjugated with horseradish peroxidase, and the protein was detected using chemiluminescence method followed by autoradiography. Antibodies used for immunoprecipitations and Western blot analyses were as follows: anti-γ-synuclein antibody (goat polyclonal antibody E20, 1:300 dilution); anti-ER-α antibody (rabbit polyclonal antibody HC-20, 1:300 dilution); anti-Hsp-70 antibody (goat polyclonal antibody sc-1060; 1:1000 dilution); anti-heat shock cognate 70 antibody (goat polyclonal antibody, 1:1000 dilution); anti-Hsp-90 antibody (rabbit polyclonal antibody sc-7947; 1:1000 dilution); normal goat IgG (sc-2028); normal rabbit IgG (sc-2027); and anti-actin antibody (goat polyclonal antibody sc-1615). These antibodies were from Santa Cruz Biotechnology. Anti-phospho-estrogen receptor α (Ser167; 1:500 dilution), anti-phospho-Akt (Ser473; 1:500 dilution) and anti-Akt (1:1000 dilution) are from Cell Signaling Technology (Beverly, MA).

**Ligand-Binding Assay.** MCF-7 cells were plated into 24-well plate at 50,000 cells/well and cultured in estrogen-free medium for 3 days before the binding assay. E2 binding by ER was assayed by measuring the bound [3H]estradiol following a 1.5-h incubation with different concentrations of [3H]estradiol as follows: 0, 0.0025, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, and 10 nM. Cells were then washed three times with 0.5 ml of PBS and dissolved with 0.1 ml of 0.1 N NaOH. The cell lysate was transferred into a 1.5-ml Eppendorf tube and neutralized with 0.1 ml of 0.1 M NaAc. Aliquots of 150 μl were counted in a liquid scintillation counter. Counts from samples, which were incubated with a 100-fold excess of unlabeled E2 (nonspecific binding), were subtracted from the total counts to give the values for specific ligand binding. Triplicate wells were assayed for each condition. Each value was normalized against the protein concentration.

**Assays for the Transcriptional Activity of ER-β.** Cells were transiently transfected with a firefly luciferase reporter construct (pERE4-Luc) containing four copies of the estrogen response element (ERE). For the cotransfection experiments, the plasmid DNA ratio of pERE4Luc to expression vectors of ER-β or SNCG was 2:1. A Renilla luciferase reporter, pRL-SV40-Luc, was used as an internal control for transfection efficiency. Luciferase activities in total cell lysate were measured using the Promega Dual Luciferase Assay System. Absolute ERE promoter firefly luciferase activity was normalized against Renilla luciferase activity to correct for transfection efficiency. Triplicate wells were assayed for each transfection condition and at least three independent transfection assays were performed.

**Tumor Growth in Athymic Nude Mice.** A nude mouse tumorigenesis assay was performed as we described previously (14). Briefly, estrogen pellets (0.72 mg/pellet; Innovative Research of America, Toledo, OH) were implanted s.c. in athymic nude mice (experiment 1) and in some ovarioctomized athymic nude mice (experiment 2; Frederick Cancer Research and Development Center, Frederick, MD). Approximately 5 × 10^6 cells (experiment 1) or 1.5 × 10^5 cells (experiment 2) were injected into a 6-week old female athymic nude mouse. Each animal received two injections, one on each side, in the mammary fat pads between the first and second nipples. Tumor size was determined at weekly intervals by three-dimensional measurements (mm) using a calliper. Only measurable tumors were used to calculate the mean tumor volume for each tumor cell clone at each time point.

**RESULTS**

**SNCG Participated in the Hsp-Based Multiprotein Chaperone Complex for ER-α.** It is well documented that the activation of steroid receptors is modulated by a heterocomplex with several molecular chaperones, particularly with Hsp90 and Hsp70, which associate with the unliganded steroid receptors and maintain them in a high-affinity hormone-binding conformation (23–26). The chaperone-like activity of synucleins has been demonstrated in the cell-free system by monitoring the aggregation of thermally denatured proteins (27). Because SNCG stimulated ligand-dependent transcriptional activity of ER-α, which can be blocked by antiestrogen (16), we reason that SNCG may have a chaperone activity and participate in Hsp-based multiprotein chaperone complex for ER-α. In this regard, we investigated if SNCG can physically and functionally interact with ER-α, Hsp70, and Hsp90 in SNCG-transfected MCF-7 cells by co-immunoprecipitation assays. Immunoprecipitation of ER-α coprecipitated SNCG, Hsp70, and Hsp90 in the absence of estrogen (Fig. 1A) and vice versa (Fig. 1B), indicating that SNCG participated in a heterocomplex with Hsp90, Hsp70, and ER-α in the absence of estrogen. However, SNCG dissociated from ER-α after cells were treated with E2 (Fig. 1C). The binding pattern of SNCG to the unliganded ER-α is same to that of Hsp90 and Hsp70, which only bind to the unliganded ER-α (24). Similar to its binding pattern to ER-α, SNCG only bound to Hsp90 in the absence of estrogen (Fig. 1B). After cells were treated with E2, the liganded ER-α dissociated from SNCG, Hsp70, and Hsp90 (Fig. 1C). However, in contrast to its binding pattern to ER-α and Hsp90, SNCG was found to bind to Hsp70 under the conditions both without (Fig. 1B) and with E2 (Fig. 1D), indicating that SNCG binds to Hsp70 constitutively regardless of whether Hsp70 is associated with ER-α.

We also investigated the interactions among endogenous SNCG,
ER-α and Hsp. T47D cells express both SNCG and ER-α and therefore were chosen to study the interaction between SNCG and ER-α and Hsp in the physiological situation. Same interaction pattern between endogenous SNCG and ER-α and Hsp was observed in T47D cells as that we demonstrated in SNCG transfected MCF-7 cells (Fig. 2). When T47D cells were cultured under the estrogen-free conditions, endogenous SNCG was immunoprecipitated with ER-α, Hsp70, and Hsp90 (Fig. 2A). However, after the treatment of E2, SNCG dissociated from ER-α and Hsp90 but still bound to Hsp70 (Fig. 2B), indicating that the interaction between the endogenous SNCG, ER-α, Hsp70, and Hsp90 proteins also occurs in the physiological situation. In addition, SNCG also bound to heat shock cognate 70, the cognate form of Hsp70 (Fig. 2C).

**SNCG Enhances Ligand Binding by ER.** It has been proposed that Hsp90-based chaperone complex inactivates the ER’s transcriptional regulatory capabilities and maintains the ER in a conformation competent for steroid binding (24). We examined whether the SNCG-stimulated hormone-dependent ER-α transactivation results from increased E2 binding by the receptor. This was investigated by detecting the hormone-binding activity of ER using a ligand-binding assay in MCF-7 cells. In this experiment, growing cell cultures were treated with [3H]labeled E2 over a range of hormone concentrations. As shown in Fig. 3, SNCG significantly enhanced ligand binding by ER. The biggest increases in the ligand binding were observed at the lower concentration range of 0.0025–1 nM ligand. At the concentration of 1 nM E2, the ligand binding was increased 160% in the SNCG-positive cells versus the SNCG-negative control cells. Although the levels of SNCG-enhanced ligand binding were gradually decreased with the increasing concentrations of ligand, the stimulated ligand binding was still considerably significant. At the concentration of 10 nM E2, SNCG overexpression led to a 50% increase in the ligand binding. However, no difference in ligand binding was observed between MCF-7-neo and MCF-7-SNCG cells at 100 nM E2 (data not shown). These data suggest that SNCG enhances ER’s ability to respond to low levels of ligand.

The binding data are complex because there are two binding states that differed in their affinity for the hormone. As revealed by Scatchard analysis (Fig. 4), the cutoff value for estrogen concentration to differentiate high- from low-affinity binding is 1 nM. The high-affinity state was apparent in a linear plot between 0.0025 and 1 nM E2, and the low-affinity state between 1 and 10 nM E2. The existence of both high- and low-affinity states of steroid receptors have been observed previously (28). To more closely examine the effect of SNCG on high-affinity ligand binding, data in Fig. 4C shows the high-affinity binding state in MCF-7-neo and MCF-7-SNCG cells. SNCG overexpression significantly enhanced the high-affinity state of ER in MCF-7 cells, resulting in a 2.3-fold increase in high-affinity binding capacity. Although the high-affinity binding capacity in MCF-7-neo cells was saturated when the bound E2 reached 0.06 pmol/mg protein, the high-affinity binding capacity in MCF-7-SNCG cells was saturated when the bound E2 reached 0.14 pmol/mg protein. These data indicate that SNCG affects ER-α signal transduction pathway at the step of ligand binding by increasing the number of high-affinity ligand-binding sites.

---

**Fig. 2. Interaction between endogenous γ synuclein (SNCG), estrogen receptor (ER-α), heat-shock protein (Hsp)70, heat-shock cognate (Hsc)70, and Hsp90 in T47D cells.** A, association of endogenous SNCG with ER-α, Hsp70, and Hsp90 in the absence of estradiol (E2). Total cell lysates were isolated from the cells cultured in the E2-free conditioned medium, and equal amounts of protein were subjected to immunoprecipitation (IP) with anti-ER-α, anti-SNCG antibodies, and normal IgG. The immunoprecipitates were analyzed for Hsp70, SNCG, Hsp90, and ER-α after Western blotting using anti-Hsp70, anti-SNCG, anti-Hsp90, and anti-ER-α antibodies. B, association of endogenous SNCG with Hsp70 in the presence of E2. Total cell lysates were isolated from the cells cultured in the conditioned medium containing 10 nM E2, and equal amounts of protein were subjected to IP with anti-SNCG antibody and normal goat IgG. The nontransfected MCF-7 cell lysates were also subjected to IP as a negative control for SNCG IP. The immunoprecipitates were subjected to Western blotting using antibodies against Hsp70, SNCG. C, association of endogenous SNCG with Hsc70. Lysates from T47-D cells were subjected to IP with anti-SNCG antibody and normal goat IgG. The immunoprecipitates were subjected to Western blotting using antibodies against Hsc70, SNCG.

**Fig. 3. Estrogen-binding capability for estrogen receptor in γ synuclein (SNCG)-transfected MCF-7 cells (MCF-7-SNCG) and control neo-transfected cells (MCF-7-Neo).** Cells were transiently transfected with pcDNA-SNCG or pcDNA-neo plasmids. The transfected cells were enriched with Neomycin selection for 12 days before the hormone-binding assay. A, Western blot analysis of SNCG expression in pooled SNCG-transfected MCF-7 cells after selection with G418. B, titration of [3H]estradiol (E2) in MCF-7-Neo and MCF-7-SNCG cells. Inset, enlarged view of [3H]E2 titration from 0 to 1 nM of ligand.
To address whether the stimulatory effect of SNCG on ER-α ligand-binding activity is mediated by Hsp chaperone activity, we investigated the effect of the Hsp90 inhibitor GA on the ligand-binding activity of ER-α in MCF-7-neo cells and MCF-7-SNCG cells. GA inhibits the ATPase activity of Hsp90. We first analyzed the effect of GA treatment on ER-α levels. As demonstrated in Fig. 5A, transfection of SNCG gene into the SNCG-negative MCF-7 cells did not affect ER-α expression under the conditions with or without GA treatment. In the absence of GA, the basal levels of ER-α in control and SNCG-transfected cells are the same. Although treatment of the control cells with GA resulted in a decrease in ER-α levels, overexpression of SNCG did not affect GA-mediated degradation of ER-α. We next investigated the effect of GA on the ER-α ligand-binding activity in MCF-7-neo and MCF-7-SNCG cells. In the absence of GA, SNCG increased the ligand-binding capability of ER-α by 91%. Upon the treatment with GA, although considerable amounts of ER-α protein were still present in both MCF-7-neo and MCF-7-SNCG cells, the ligand-binding activity of ER-α in both cells was abolished (Fig. 5B). This data indicates that the stimulatory effect of SNCG on ER-α activity is Hsp dependent.

SNCG Did Not Affect Phosphorylation of ER-α. To additionally determine the molecular mechanisms for SNCG-stimulated ER-α transcriptional activity, we also studied if SNCG regulates ligand-dependent or ligand-independent phosphorylation of ER-α. Although E2 directly binds to and activates ER, thereby enhancing estrogen-responsive genes transcription, ER-α can also be activated by ligand-independent phosphorylation, which is mediated by cytoplasmic proteins and signaling pathways such as mitogen-activated protein kinase- and Akt-mediated phosphorylation (29). Many growth factors such as epidermal growth factor can also activate ER-α by such cytoplasmic signaling pathways. As expected, treatment of MCF-7 cells with E2 resulted in decreased levels of ER-α and stimulated Ser167 phosphorylation of ER-α. However, transfection of SNCG to MCF-7 cells didn’t enhance Ser167 phosphorylation of ER-α in response to E2 compared with mock-transfected cells (Fig. 6A). There was also no significant difference in Ser104 or Ser118 phosphorylation of ER-α (data not shown). In addition, SNCG overexpression in MCF-7 cells didn’t enhance the phosphorylation of Akt in response to both E2 and epidermal growth factor (Fig. 6B).

Effect of SNCG on Transcriptional Activity of ER-β. In an effort to address whether SNCG has general effect on other steroid hormone receptors relevant in breast cancer, we investigated the effect of SNCG on the transcriptional activity of ER-β. Because both ER-α and ER-β bind to the same EREs, we cotransfected ER-α-negative MDA-MB-435 cells with ER-β and ER reporter ERE4-luciferase (Fig. 7). In contrast to the previously demonstrated stimulation of ER-α signaling (16), SNCG did not stimulate the transactivation of ER-β. When cells were treated with E2, a 15.7- and 13.5-fold increase relative to basal levels in ER-β reporter activity was observed in SNCG-negative and SNCG-positive cells, respectively. Therefore, expression of SNCG in breast cancer cells stimulates the transcriptional activity of ER-α but not ER-β, indicating that SNCG may not have a general effect on stimulation of transcriptional activity of steroid receptors.

Fig. 4. Scatchard analysis of the ligand binding by estrogen receptor from MCF-7-Neo cells (A) and MCF-7-SNCG cells (B). Solid line, high-affinity sites; dashed line, low-affinity sites. C, the high-affinity sites of MCF-7-Neo and MCF-7-SNCG cells. Specific binding was determined by subtracting the nonspecific binding from samples incubated with 100-fold excess of nonlabeled estradiol (E2). Each data point is the mean ± SD of triplicate samples.

Fig. 5. Effect of heat-shock protein (Hsp90) inhibitor geldanamycin (GA) on estrogen-binding capability of estrogen receptor (ER) in MCF-7 cells. A, Western blot analysis of ER and γ synuclein (SNCG) levels in pooled MCF-7-Neo and MCF-7-SNCG cells treated with or without GA. The pooled MCF-7-Neo and MCF-7-SNCG cells were cultured in the presence of 0.1 mM estradiol (E2) and treated with or without 0.25 μg GA for 24 h. Cell lysates were normalized and subjected to Western blot analysis using the antibody against ER-α, SNCG, and actin, respectively. B, GA abolished the stimulatory effect of SNCG on estrogen-binding capability in MCF-7 cells. MCF-7-Neo and MCF-7-SNCG cells were treated with or without 0.25 μg GA for 24 h followed by the ligand binding assay with 0.1 nM [3H]E2. The data were presented as the percentage of the nontreated MCF-7-Neo controls, which was taken as 100%. Each data represent the mean ± SD of triplicate cultures.
with or without 10^{-9} M estradiol (E_2) or 50 ng/ml epidermal growth factor (EGF). Cell lysates were subjected to Western blot analysis using the antibodies against human AKT and Ser473-phosphorylated AKT, respectively. SNCG overexpression didn’t affect E_2 and EGF-induced ERα phosphorylation. A, MCF-7 cells were transiently transfected with pCI-SNCG or pCI-neo plasmids. After G418 selection for 12 days, the pooled population of transfected cells were treated with or without 10^{-8} M E_2 or 50 ng/ml EGF for 15 min. Cell lysates were subjected to Western blot analysis using the antibodies against human Ser167-phosphorylated ERα, ERα, and actin, respectively. SNCG overexpression didn’t affect E_2 and EGF-induced AKT phosphorylation.

The tumor growth of MCF-SNCG2 cells was also significantly stimulated, with 3.5- and 2.7-fold increase in tumor size as compared with MCF-neo2 and MCF-neo1 tumors, respectively. Fig. 7 shows that MCF-SNCG2 and MCF-SNCG6 clones were significantly enhanced compared with that of MCF-neo1 and MCF-neo2 clones. Thus, the tumorogenesis of MCF-7 cells in response to E2 was significantly stimulated by SNCG overexpression.

We then analyzed the requirement of E_2 for SNCG-mediated tumor growth. Two independent experiments under different conditions were done to determine the effects of SNCG on mammary tumorigenesis. We first analyzed the tumorigenesis in response to E_2 in nonovariectomized mice. It was previously demonstrated that the circulating E_2 level in the nonovariectomized mice is about 26 pg/ml (30), which compares to the low levels found in postmenopausal women (31). To override the endogenous levels of estrogen, all of the mice were supplemented with E_2 (0.72 mg/pellet) 1 day before injection of 5 × 10^6 cells. After a lag phase of 8–10 days, 29 of 32 (91%) injections in the mice given implants of SNCG-positive MCF-SNCG2 and MCF-SNCG6 cells developed tumors. In contrast, only 21 of 32 (66%) injections in the mice given implants of SNCG-negative MCF-neo1 and MCF-neo2 cells developed tumors (Table 1).

<table>
<thead>
<tr>
<th>Experiment group</th>
<th>E_2</th>
<th>Tumor/Total(%) Day 21</th>
<th>Tumor/Total(%) Day 35</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-SNCG2</td>
<td>+</td>
<td>14/16 (88)</td>
<td>234 ± 69</td>
</tr>
<tr>
<td>MCF-SNCG6</td>
<td>+</td>
<td>15/16 (94)</td>
<td>351 ± 78</td>
</tr>
<tr>
<td>MCF-neo1</td>
<td>+</td>
<td>10/16 (63)</td>
<td>101 ± 39</td>
</tr>
<tr>
<td>MCF-neo2</td>
<td>+</td>
<td>11/16 (69)</td>
<td>123 ± 25</td>
</tr>
</tbody>
</table>

*Cells were injected into the mammary fat pads, and tumor volumes and tumor incidence were determined as described in “Materials and Methods.” Each mouse received two injections. Tumor volumes were measured at 21 and 35 days after cell injection and are expressed as means ± SEs (number of tumors assayed). All the nonovariectomized mice received an estrogen implantation 1 day before the cell injection. There were total 16 injections for 8 mice in each group, and each injection had 5 × 10^6 cells. Statistical comparisons for SNCG-positive clones relative to SNCG-negative clones indicated P < 0.01 for the mean tumor sizes and P < 0.05 for the tumor incidence. Statistical comparison for primary tumors was analyzed by Student’s t test. A χ^2 test was used for statistical analysis of tumor incidence. SNCG, γ synuclein; E_2, estradiol.

Stimulation of Estrogen-Dependent Mammary Tumorigenesis by SNCG. An orthotopic nude mouse model was used to study the effects of SNCG on tumor growth. Two independent experiments under different conditions were done to determine the effects of SNCG on mammary tumorigenesis. We first analyzed the tumorigenesis in response to E_2 in nonovariectomized mice. It was previously demonstrated that the circulating E_2 level in the nonovariectomized mice is about 26 pg/ml (30), which compares to the low levels found in postmenopausal women (31). To override the endogenous levels of estrogen, all of the mice were supplemented with E_2 (0.72 mg/pellet) 1 day before injection of 5 × 10^6 cells. After a lag phase of 8–10 days, 29 of 32 (91%) injections in the mice given implants of SNCG-positive MCF-SNCG2 and MCF-SNCG6 cells developed tumors. In contrast, only 21 of 32 (66%) injections in the mice given implants of SNCG-negative MCF-neo1 and MCF-neo2 cells developed tumors (Table 1). The tumor growths in MCF-SNCG clones were significantly stimulated. At 35 days after tumor cell injection, the size of MCF-SNCG6 tumors, which expressed a relative high level of SNCG mRNA, was 4.8-fold of that in parental MCF-neo2 tumors and 3.7-fold of that in MCF-neo1 tumors. In addition, the tumor incidence was also increased. With 16 injections, whereas 15 implants in MCF-SNCG6 cells developed tumors, only 10 implants from MCF-neo1 and 11 implants from MCF-neo2 developed tumors, respectively. The tumor growth of MCF-SNCG2 cells was also significantly stimulated, with 3.5- and 2.7-fold increase in tumor size as compared with MCF-neo2 and MCF-neo1 tumors, respectively. Fig. 8 shows growth kinetics. After a slow growth phase of 14 days, tumor growth of MCF-SNCG2 and MCF-SNCG6 clones were significantly enhanced as compared with that of MCF-neo1 and MCF-neo2 clones. Thus, the tumorogenesis of MCF-7 cells in response to E2 was significantly stimulated by SNCG overexpression.

We then analyzed the requirement of E_2 for SNCG-mediated tumor growth. Two independent experiments under different conditions were done to determine the effects of SNCG on mammary tumorigenesis. We first analyzed the tumorigenesis in response to E_2 in nonovariectomized mice. It was previously demonstrated that the circulating E_2 level in the nonovariectomized mice is about 26 pg/ml (30), which compares to the low levels found in postmenopausal women (31). To override the endogenous levels of estrogen, all of the mice were supplemented with E_2 (0.72 mg/pellet) 1 day before injection of 5 × 10^6 cells. After a lag phase of 8–10 days, 29 of 32 (91%) injections in the mice given implants of SNCG-positive MCF-SNCG2 and MCF-SNCG6 cells developed tumors. In contrast, only 21 of 32 (66%) injections in the mice given implants of SNCG-negative MCF-neo1 and MCF-neo2 cells developed tumors (Table 1). The tumor growths in MCF-SNCG clones were significantly stimulated. At 35 days after tumor cell injection, the size of MCF-SNCG6 tumors, which expressed a relative high level of SNCG mRNA, was 4.8-fold of that in parental MCF-neo2 tumors and 3.7-fold of that in MCF-neo1 tumors. In addition, the tumor incidence was also increased. With 16 injections, whereas 15 implants in MCF-SNCG6 cells developed tumors, only 10 implants from MCF-neo1 and 11 implants from MCF-neo2 developed tumors, respectively. The tumor growth of MCF-SNCG2 cells was also significantly stimulated, with 3.5- and 2.7-fold increase in tumor size as compared with MCF-neo2 and MCF-neo1 tumors, respectively. Fig. 8 shows growth kinetics. After a slow growth phase of 14 days, tumor growth of MCF-SNCG2 and MCF-SNCG6 clones were significantly enhanced as compared with that of MCF-neo1 and MCF-neo2 clones. Thus, the tumorogenesis of MCF-7 cells in response to E2 was significantly stimulated by SNCG overexpression.

We then analyzed the requirement of E_2 for SNCG-mediated tumor growth. Two independent experiments under different conditions were done to determine the effects of SNCG on mammary tumorigenesis. We first analyzed the tumorigenesis in response to E_2 in nonovariectomized mice. It was previously demonstrated that the circulating E_2 level in the nonovariectomized mice is about 26 pg/ml (30), which compares to the low levels found in postmenopausal women (31). To override the endogenous levels of estrogen, all of the mice were supplemented with E_2 (0.72 mg/pellet) 1 day before injection of 5 × 10^6 cells. After a lag phase of 8–10 days, 29 of 32 (91%) injections in the mice given implants of SNCG-positive MCF-SNCG2 and MCF-SNCG6 cells developed tumors. In contrast, only 21 of 32 (66%) injections in the mice given implants of SNCG-negative MCF-neo1 and MCF-neo2 cells developed tumors (Table 1). The tumor growths in MCF-SNCG clones were significantly stimulated. At 35 days after tumor cell injection, the size of MCF-SNCG6 tumors, which expressed a relative high level of SNCG mRNA, was 4.8-fold of that in parental MCF-neo2 tumors and 3.7-fold of that in MCF-neo1 tumors. In addition, the tumor incidence was also increased. With 16 injections, whereas 15 implants in MCF-SNCG6 cells developed tumors, only 10 implants from MCF-neo1 and 11 implants from MCF-neo2 developed tumors, respectively. The tumor growth of MCF-SNCG2 cells was also significantly stimulated, with 3.5- and 2.7-fold increase in tumor size as compared with MCF-neo2 and MCF-neo1 tumors, respectively. Fig. 8 shows growth kinetics. After a slow growth phase of 14 days, tumor growth of MCF-SNCG2 and MCF-SNCG6 clones were significantly enhanced as compared with that of MCF-neo1 and MCF-neo2 clones. Thus, the tumorogenesis of MCF-7 cells in response to E2 was significantly stimulated by SNCG overexpression.
stimulation under more stringent conditions, including use of ovariectomized mice and reduction of injected tumor cells from $5 \times 10^6$ to $1.5 \times 10^6$. As shown in Table 2, when the number of injected MCF-neo1 cells was reduced, the tumor incidence was greatly reduced from 63% to 0%, both in the absence and presence of E$_2$ supplement for up to 4 weeks, indicating a nontumorigenic condition for SNCG-negative MCF-7 cells even with estrogen stimulation for 4 weeks. At week 7, a 30% of tumor incidence with small tumor size (44 mm$^3$) was observed. However, for MCF-SNCG6 cells, although the same nontumorigenic phenotype was observed under the conditions with reduced cell number and in the absence of E$_2$ when E$_2$ was supplemented, the tumor incidence reached 90% 3 weeks after cell inoculation, which is similar to 94% of tumor incidence in the experiment with higher injected cell numbers (Table 1). Furthermore, the tumor size of SNCG-positive cells is 4.4-fold of control. These data indicate that estrogen is necessary for SNCG-mediated tumor stimulation in this xenograft model.

**DISCUSSION**

Synucleins are small proteins expressed predominately in neurons and have been specifically implicated in neurodegenerative disorders such as AD and PD. However, SNCG was first identified and cloned as a breast cancer specific gene, which is highly expressed in advanced infiltrating breast carcinomas but not in normal or benign breast tissues (1). Aberrant expression of SNCG was also associated with ovary cancer progression (4, 19). The association between SNCG expression and the progression of steroid-dependent cancers of breast and ovary suggest a potential role of SNCG in regulation of ER-α. Previously, we demonstrated a SNCG-stimulated ER-α signaling in three different cell systems, including (a) overexpression of SNCG in ER-α-positive and SNCG-negative MCF-7 cells, (b) antisense blockage of SNCG expression in ER-α-positive and SNCG-positive T47D cells, and (c) cotransfection of SNCG and ER-α into SNCG-negative and ER-α-negative MDA-MB-435 cells (16). The results shown in this study demonstrated that SNCG stimulated mammary tumorigenesis in response to estrogen, which is mediated by its participation in Hsp-based chaperone complex for regulation of ER-α transcriptional activity.

To acquire the ability to bind hormone, steroid hormone receptors undergo a series of transformation steps in which they are brought into the correct conformation by molecular chaperones and cochaperones. The most extensively studied chaperones for steroid receptors are a multiprotein Hsp70- and Hsp90-based chaperone system, which includes Hsp90, Hsp70, Hop, Hsp40, p23, and others (23, 24). Hsp70 and Hsp90 associate with the unliganded steroid hormone receptors and maintain the conformational state for efficient ligand binding and receptor activation. Consistent with the previous report on chaperone-like activity of synucleins (27), here, we provided evidences suggesting that SNCG is a new member of molecular chaperone proteins that participates in Hsp-based chaperone complex for regulating ER-α activity. These evidences include that (a) SNCG bound to the unliganded form of ER-α, Hsp90, and Hsp70, (b) SNCG enhanced the high-affinity ligand-binding state of ER, and (c) SNCG significantly stimulated the transcriptional activity of ER-α and ligand-dependent mammary tumorigenesis. The binding of SNCG to ER-α and Hsp90 only occurs in the absence of ligand, which is same to the binding of Hsp90 and Hsp70 to the unliganded ER-α. However, the binding between SNCG and Hsp90 was observed under the conditions both with and without the ligand, suggesting that SNCG is an Hsp70-binding protein.

It has been previously demonstrated in the cell-free system that Hsp70-free reticulocyte lysate is inactive at glucocorticoid receptor heterocomplex formation with Hsp90 and that the activity is restored by readdition of purified Hsp70 (32, 33), indicating that the binding of Hsp70 to the unliganded steroid receptor is necessary for the efficient Hsp90 binding for maintaining the high transcriptional activity of steroid receptors. Hsp90 is absolutely essential for hormone binding to glucocorticoid receptor under all conditions (34). Recent studies from in vivo yeast system and in vitro mammalian cell-free system also indicate that ER requires the molecular chaperone Hsp90 for efficient hormone binding (35). There were two pools of ER, one with high hormone affinity and one with low affinity (Fig. 4). Although the nature of the low-affinity state is unclear, its existence in cells may reflect an equilibrium between the receptors with high hormone affinity and poised for activation and those with low affinity. The low-affinity hormone-binding state may reflect a kinetically trapped folding intermediate that requires the action of SNCG, Hsp90, and other proteins for the conversion into the high-affinity state. A working model for the role of SNCG on ER-α transcriptional activation is presented in Fig. 9. In this model, SNCG binds to Hsp70 and forms a complex including Hsp90, Hsp70, SNCG, ER-α, and others. This model includes interaction between SNCG and Hsp90, Hsp70, Hop, and p23. The interaction between SNCG and Hsp90 is necessary for the efficient ligand binding and receptor activation. This model is consistent with the previous report on chaperone-like activity of synucleins (27).

### Table 2. Stimulation of estrogen-mediated tumorigenesis by SNCG$^{ab}$

<table>
<thead>
<tr>
<th>Group</th>
<th>E$_2$</th>
<th>Week 1</th>
<th>Week 2</th>
<th>Week 3</th>
<th>Week 4</th>
<th>Week 5</th>
<th>Week 6</th>
<th>Week 7</th>
<th>Tumor volume (mm$^3$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-neo1</td>
<td>-</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>44 ± 10</td>
</tr>
<tr>
<td>MCF-neo1</td>
<td>+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>20</td>
<td>30</td>
<td>30</td>
<td>194 ± 35</td>
</tr>
<tr>
<td>MCF-SNCG6</td>
<td>-</td>
<td>40</td>
<td>80</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>MCF-SNCG6</td>
<td>+</td>
<td>40</td>
<td>80</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td></td>
</tr>
</tbody>
</table>

$^a$ Ovariectomized mice were treated with or without E$_2$ pellet. There were total 10 injections for 5 mice in each group, and each injection had $1.5 \times 10^6$ cells. Only measurable tumors were used to calculate the mean tumor volume. Statistical comparisons for SNCG-positive clones relative to SNCG-negative clones indicated $P < 0.001$ for both tumor incidence and mean tumor sizes in the presence of E$_2$.

$^b$ SNCG, γ synuclein; E$_2$, estradiol.
chaperone complex pushes the equilibrium toward the high-affinity hormone-binding conformation. Although the nature of the conformational changes in ER-α is unknown, SNCG overexpression would be expected to result in a greater number of mature ER complexes with high-affinity ligand-binding capability. As a result, the physiological levels of E₂ binding will increase, which is consistent with the E₂-binding assays (Figs. 3 and 4). Thus, overexpression of SNCG, by increasing the number of mature receptor complexes with high-affinity ligand-binding capability, will manifest itself as an increase in transcriptional activation by ER at a given hormone concentration.

One of the critical questions need to be addressed is whether SNCG-stimulated ER-α transactivation is mediated by a Hsp-based chaperone complex, particularly Hsp70. Using Hsp90 inhibitor GA, our data demonstrated that treatment of cells with GA completely abolished SNCG-stimulated receptor ligand binding, indicating that the SNCG-mediated stimulation of ER-α is Hsp dependent. However, this study needs to be additionally confirmed with more specific approaches such as small interfering RNAs to knock out Hsp70 or Hsp90. We realize that Hsp70 and Hsp90 play a critical role in maintaining ER-α in a right conformation for ligand binding. Without chaperone activity of Hsp70 and Hsp90, the transcriptional activity of ER-α might not be efficiently activated. In this regard, inhibition of endogenous levels of Hsp70 or Hsp90 by small interfering RNA may greatly affect ER-α transactivation, and thus, the SNCG-mediated stimulation of ER-α transactivation may be jeopardized. SNCG may also regulate ER-α signaling by Hsp-independent pathways such as direct binding to and chaperoning ER-α. However, our *in vitro* translation study indicates that SNCG did not physically interact with ER-α directly (data not shown). Nevertheless, our model suggests that SNCG-stimulated transcriptional activity of ER-α is mediated, at least in part, by participating in Hsp-based multiprotein chaperone complex and maintaining the ER-α in a high-affinity hormone-binding conformation. Thus, SNCG and Hsps act cooperatively in ER-α signaling.

The SNCG-mediated stimulation of ER-α transcriptional activity is consistent with its stimulation of the ligand-dependent cell growth. It has been demonstrated in different systems that the interaction between SNCG and ER-α stimulated cell growth in response to estrogen. First, although expression of SNCG in MCF-7 cells had no effect on the cell growth in the absence of E₂, SNCG significantly stimulated the ligand-dependent cell growth, which can be blocked by antiestrogens (16). This growth stimulation was also previously demonstrated in the anchorage-independent growth assay (15). Second, when endogenous SNCG expression in T47D cells was blocked by expressing SNCG antisense mRNA, the anchorage-independent growth in response to E₂ was significantly suppressed in the cells expressing antisense SNCG (16). Third, although the alteration of SNCG expression affected the cell growth of ER-α-positive MCF-7 and T47D cells, it had no effect on the cell growth of ER-α-negative MDA-MB-435 cells (14). Finally, SNCG overexpression significantly stimulated the tumorigenesis of MCF-7 cells in response to estrogen, whereas it has no effect on tumor growth in the absence of estrogen. Consistent with the requirement of E₂ for SNCG-stimulated tumor growth, it was demonstrated that SNCG had no significant effect on tumor growth of ER-α-negative MDA-MB-435 cells (14).

We isolated a 2195-bp promoter fragment of a human SNCG gene and demonstrated that demethylation of exon 1 region of SNCG gene is an important factor responsible for the aberrant expression of SNCG in breast carcinomas (21, 22). However, the molecular targets of SNCG aberrant expression in breast cancer have not been identified. Our findings suggest that SNCG functions as a chaperone and participates in Hsp-based multiprotein chaperone system for efficient activation of ER-α. Thus, aberrant expression of SNCG stimulates breast cancer growth and progression, at least in part, by enhancing the transcriptional activity of ER-α. The role of SNCG in breast cancer progression may also involve other non-ER-mediated functions such as stimulation of tumor motility and metastasis as we previously described in hormone-independent breast cancer cells (14).

The cellular functions of synucleins remain elusive. Although the chaperone-like activity has been suggested for synucleins based on the cell-free system (27), the molecular targets for chaperone activity remain to be identified. Recently, the protective effect of molecular chaperone Hsp70 on SNCA-induced dopaminergic neuronal loss in *Drosophila* has been reported (36), indicating that chaperone activity of Hsp70 helps to protect neurons against the neurotoxic consequences of SNCA expression. Interestingly, although filamentous SNCA is the major deposit in intracerebral inclusions in neurons, SNCG and SNCB inhibit SNCA fibril formation, suggesting a protective effect of SNCG and SNCB on SNCA aggregation (37). SNCG-mediated chaperone activity on ER-α may indicate a new direction of normal cellular function of synucleins. In this regard, SNCG may be involved in regulating Hsp70 and mediating the activation of ER-α in neuronal cells; thus, the down-regulation of SNCG expression may lower the beneficial effects of estrogen on protecting neurons against PD and AD. The potential role of SNCG as a neuroprotectant warrants additional investigation. Demonstration of direct interaction with ER-α chaperone complex and stimulation of ER-α signaling as one of the cellular functions of SNCG not only support its pathological role in the growth of steroid-responsive tumors but may also shed some light on the cellular functions of synucleins in brain cells and their complex roles in the development of neurodegenerative disorders.

**ACKNOWLEDGMENTS**

We thank Dr. Jan-Ake Gustafsson for providing human ER-β expression vector pSG5-hERβ.

**REFERENCES**

11. Yoshimoto M, Iwai A, Kang D, Otero DA, Xia Y, Saitoh T. NACP, the precursor of SYNUCLEIN γ stimulates estrogen receptor signaling as one of the cellular functions of SNCG not only support its pathological role in the growth of steroid-responsive tumors but may also shed some light on the cellular functions of synucleins in brain cells and their complex roles in the development of neurodegenerative disorders.
SYNUCLEIN γ STIMULATES ESTROGEN RECEPTOR SIGNALING

Synucleins are emerging as central players in the formation of pathologically insoluble deposits characteristic of neurodegenerative diseases. However, synuclein \( \gamma \) (SNCG), previously identified as a breast cancer specific gene (BCSG1), is also highly associated with breast cancer progression. Using transgenic mouse model, we demonstrated a role of SNCG in induction of highly proliferative pregnancy-like phenotype of mammary epithelial cells and branching morphology. SNCG participated in the heat shock protein-based multiprotein chaperone complex for steroid receptor signaling. Expression of SNCG in mammary epithelium resulted in a significant stimulation of ER\( \alpha \) transcriptional activity. SNCG-induced mammary gland proliferation can be effectively blocked by antiestrogen and ovariectomy, indicating that the induced proliferation is mediated by ER\( \alpha \) signaling and requires estrogen stimulation. These data indicate the chaperone activity of SNCG on stimulation of steroid receptor signaling in mammary gland and, thus induces extensive mammary gland proliferation and contributes to the hormonal impact on mammary tumorigenesis.

Oncogene (2006) 0, 000–000. doi:10.1038/sj.onc.1210000

Introduction

We have previously reported the isolation of differentially expressed genes in the cDNA libraries from normal breast and infiltrating breast cancer using differential cDNA sequencing approach (Ji et al., 1997; Shi et al., 1997; Xiao et al., 1999). Of many putative differentially expressed genes, a breast cancer specific gene BCSG1 was identified as a putative breast cancer marker. This gene was highly expressed in the advanced breast cancer cDNA library but scarce in a normal breast cDNA library (Ji et al., 1997). Interestingly, BCSG1 revealed no homology to any other known growth factors or oncogenes. Rather, there is extensive sequence homology to neural protein synuclein. Subsequent to the isolation of BCSG1, synuclein \( \gamma \) (SNCG) (Lavedan et al., 1998) and persyn (Ninkina et al., 1998) were independently cloned from a brain genomic library and a brain cDNA library. The sequences of these two brain proteins were found to be identical to BCSG1. Thus, the previously identified BCSG1 has also been named as SNCG and is considered to be the third member of the synuclein family (Clayton and George, 1998).

Synucleins are a family of small proteins consisting of three known members, synuclein \( x \) (SNCA), synuclein \( \beta \) (SNCB) and synuclein \( \gamma \) (SNCG). Synucleins have been specifically implicated in neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Mutations in SNCA is genetically linked to several independent familial cases of PD (Polymeropoulos et al., 1997). More importantly, wild-type of SNCA is the major component of Lewy bodies in sporadic PD and in a subtype of AD known as Lewy body variant AD (Spillantini et al., 1997; Takeda et al., 1998). SNCA peptide known as nonamyloid component of plaques has been implicated in amyloidogenesis in AD (Ueda et al., 1993; Yoshimoto et al., 1995). SNCB and SNCG have also been recognized to play a role in the pathogenesis of PD and Lewy bodies cases (Galvin et al., 1999; Duda et al., 2000). Although synucleins are highly expressed in neuronal cells and are abundant in presynaptic terminals, they have also been implicated in non-neural diseases, particularly in the hormone responsive cancers of breast (Ji et al., 1997, 1999; Jiang et al., 2003, 2004; Inaba et al., 2005; Wu et al., 2003, 2006; Gupta et al., 2003a,b) and ovary (Lavedan et al., 1998; Bruening et al., 2000; Pan et al., 2002; Gupta et al., 2003a,b).

Being identified as a breast cancer specific gene, SNCG expression in breast follows a stage-specific manner (Ji et al., 1997). Overall SNCG mRNA expression was detectable in 39% of breast cancers. However, 79% of stage III/IV breast cancers were positive for SNCG expression, while only 15% of stage I/II breast cancers were positive for SNCG expression. In contrast, the expression of SNCG was undetectable in all benign breast lesions (Wu et al., 2003). Overexpression of SNCG in breast cancer cells led to a significant increase in cell motility and invasiveness in
vivo and a profound augmentation of metastasis in vivo (Jia et al., 1999), resistance to chemotherapeutic drug-induced apoptosis (Pan et al., 2002; Gupta et al., 2003), and accelerated rate of chromosomal instability (Gupta et al., 2003; Inaba et al., 2005). Overexpression of synucleins, especially SNCG, also correlated with ovarian cancer development (Lavedan et al., 1998; Bruening et al., 2000). While synucleins (α, β, and γ) expression was not detectable in normal ovarian epithelium, 87% (39 of 45) of ovarian carcinomas were found to express either SNCG or SNCB, and 42% (19 of 45) expressed all three synucleins (α, β and γ) simultaneously. The involvement of SNCG in hormone responsive cancers of breast and ovary promoted us to explore the potential role of SNCG in cellular response to estrogen. Previously, we investigated the functions of SNCG in regulating ERα transcriptional activity in human breast cancer cells in vitro. Augmentation of SNCG expression in breast cancer cells stimulated the transcriptional activity of ERα, whereas compromising endogenous SNCG expression suppressed ERα signaling (Jiang et al., 2003). In the present study, we evaluated the in vivo function of SNCG in mammary gland development and the relevance of stimulation of ERα signaling to mammary pathogenesis. The results indicated that SNCG, acting as a chaperone protein for ERα, stimulates steroid receptor signaling in mammary epithelial cells, and induces a highly proliferative pregnancy-like phenotype.

Results

Effects of expression of SNCG transgene on mammary gland development

We generated five SNCG transgenic lines and picked up one stable line named MMS1, which expressed relative high level of SNCG. Transgene expression in the mammary gland was assayed by RT–PCR and Western analyses (Figure 1). In the mammary glands from virgin MMS1 mouse, the expression of the transgene was detected by RT–PCR using the primers specific for human SNCG (Figure 1a). No signal was detected in the mRNA isolated from mammary glands of virgin wild-type females. Consistent with the transgene mRNA expression, while no SNCG protein was detected in the gland from the virgin control females, SNCG protein was highly expressed in the mammary gland from MMS1 mouse (Figure 1b). Both MMS1 mice and mice from other transgenic lines developed normally compared with their nontransgenic littermates.

The effect of transgene expression on mammary gland development was assayed by morphological analyses of ductal elongation and appearance of a branching morphogenesis. While the mammary gland development starts at about 3-week old in wild-type mice with ductal elongation, development of branching structure and functional differentiation starts at the onset of pregnancy with the expansion of secretory lobular-alveolar architecture. Whole mount preparations of the mammary glands starting at 4-week to 8-week from virgin wild-type and virgin transgenic mouse were examined to determine the effect of SNCG on early mammary gland development. Figure 2 shows a representative mammary gland analysis of 7-week old transgenic mouse vs wild-type control littermate. Mammary ducts in the transgenic virgin (Figure 2b) as well as in the control virgin littermate (Figure 2a) passed the typical half the length of the inguinal gland, completely filled with the ducts, and appeared normal. Similar ductal developments were also observed at different time points, indicating that expression of the transgene did not alter the ductal outgrowth during the early mammary gland development. However, an alternation in the developmental pattern of the branching points of ducts in transgenic virgin mouse was observed compared with the control littermate. While the limited branching was developed in the wild-type gland (Figure 2a), transgenic gland exhibited a multiplicity of branching (Figure 2b).

Induction of highly proliferative pregnancy-like phenotype proliferation

To further confirm our observation of induced branching morphology in SNCG transgenic mouse, we extended the whole mount mammary gland analysis starting at 2-month to 5-month from virgin wild-type and virgin transgenic mice to determine the effect of SNCG on development of proliferative branching morphology. Two mice were examined for each time point and data in Figure 2c–f shows a representative mammary gland analysis of 3-month and 5-month old transgenic mouse vs age-matched wild-type control littermate. A significant alternation in the developmental pattern of the branching points of ducts in transgenic virgin mice was observed compared with the control littermate. While the limited branching was developed in the wild-type gland (Figure 2c and e), transgenic gland at 3-month exhibited an increased branching morphol-
ogy and end bud density (Figure 2d). A robust increase in the branching structure at terminal end was observed in the gland from 5-month virgin transgenic mouse (Figure 2f), a phenotype similar to the stage of pregnancy.

The increased branching in the transgenic mice suggests a potential effect of SNCG on induction of proliferation of mammary epithelial cells in the end bud. We analysed the effect of SNCG on mammary epithelial cell proliferation in the transgenic mouse. We measured the percentage of cycling cells determined by BrdU incorporation in three 3-month old SNCG transgenic mice and the three age-matched control mice. While the average percent of labeled nuclei in control mice was 7.1%, expression of SNCG significantly stimulated cell proliferation with a 42% of nuclei labeled cells (Table 1). The percentage of labeled nuclei in control mice was 7.1%, expression of SNCG significantly stimulated cell proliferation with a 42% of nuclei labeled cells (Table 1). These observations are consistent with our in vitro data indicating SNCG stimulates ligand-dependent growth of human breast cancer cells (Jiang et al., 2003).

Histological evaluation of H&E-stained mammary sections also confirmed the presence of multiple branching structures in the gland from the virgin transgenic mice. There were no morphological differences observed in the younger (4- to 6-week old) transgenic mice compared to the age-matched control mice. However, starting at 10-week old, a significantly different morphology was observed in the transgenic mice vs the control mice. As shown in Figure 3, whereas no branching structures were present in the 3-month old control virgin mouse, indicating no proliferation of end bud (Figure 3a), a branching morphology (Figure 3b–c) was observed in the transgenic mice, indicating a highly

![Figure 2](image-url)

**Figure 2** Whole mount histological analysis of mammary glands from virgin SNCG transgenic mice and wild-type littermates. Control (a, c, e) and age-matched SNCG transgenic mice (b, d, f) were sacrificed, the right inguinal gland was removed and subjected to whole mount gland fix, defat and staining. (a–b) 7-week old mice. Open arrows indicate the inguinal lymph nodes. A solid arrow indicates branching morphology in the transgenic mouse. (c–d) 3-month old mice. An arrow indicates the inguinal lymph node. (e, f) 3-month old mice. Glands from transgenic mice (d, f) showed an extensive branching morphology.

<table>
<thead>
<tr>
<th>Age</th>
<th>Average BrdU labeling (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-month</td>
<td>Control 7.1 ± 2.2 Transgenic 42.51</td>
</tr>
</tbody>
</table>

BrdU was injected i.p. at a dosage of 75 mg/kg into wild-type and transgenic mice. After 2h, the mice are killed, and the right third inguinal glands are removed and processed for BrdU analysis. Tissues are fixed, processed and sectioned. BrdU is detected using a 1:400 dilution of a rat monoclonal antibody specific for BrdU (Accurate Chemicals) and avidin–biotin complex immunohistochemistry. The percentage of labeled nuclei is determined by randomly counting 500 epithelial cells in five fields (× 40) with three observers. Numbers are means ± s.d. of three mice.
proliferative capability of cells in the terminal end buds. A representative robust branching development was observed in a 5-month old transgenic mouse and illustrated in Figure 3d. Histological analysis also revealed the presence of hyperplasia-like structure in the transgenic mouse (Figure 4). Epithelium of transgenic glands exhibits a disorganized structure with respect to the ordinate arrangement of the wild-type epithelium. Furthermore, while a normal mammary gland has a single layer of epithelial cells (Figure 4a), gland from transgenic mouse displayed a highly proliferative stage characterized by areas of multilayered epithelium (Figure 4b). No carcinoma was observed in the virgin transgenic mice up to 1 year.

Stimulation of ERα signaling in mammary epithelial cells by SNCG

As expression of SNCG in mammary gland resulted in highly proliferative mammary epithelial cells in the end bud, we interested in study whether stimulation of ERα signaling is one of targets for SNCG in normal mammary epithelial cells and in vivo effect on mammary

Figure 3  Histological analysis of mammary gland. Whole inguinal glands were isolated from 3-month (a, b) and 5-month (c, d) virgin mice. All sections were stained with hematoxylin and eosin for histological analysis. (a) Control mouse. (b–d) Transgenic mice. (a–e) 10 × 10. (d) 10 × 40. The proliferation of the cells in end bud or multiple budding was clearly visible in the transgenic glands with a significant increase from the gland in 3-month (b) to the gland in 5-month mouse (e). A higher magnification (d) shows a very organized end bud proliferation and branching (arrows indicated).

Figure 4  Induction of mammary gland proliferation in SNCG transgenic mouse. A 5-month control mouse (a) and age-matched transgenic virgin mouse (b) were pre-injected i.p. with BrdU at a dosage of 75 mg/kg as described in Table 1. Inguinal glands were isolated and sections were subjected to both hematoxylin stain for histological analysis and to immunohistochemical stain with rat monoclonal antibody specific for BrdU for reviewing labeled nuclei. Nuclei labeled with brown color indicate proliferating cells. Open arrow indicates normal mammary gland. Solid arrow indicates a hyperplasia-like structure in the transgenic mouse.
SNCG would physically interact with ERα epithelial cells, we first determined if expression of SNCG co-precipitated ERα by co-immunoprecipitation assay. MCF-12A cells were transiently transfected with either the pCI-SNCG expression plasmid or control pCI-neo plasmid. In the absence of estrogen, immunoprecipitation of ERα co-precipitated SNCG and Hsp90 (Figure 5a) and immunoprecipitation of SNCG co-precipitated ERα and Hsp90 (Figure 5b), indicating that SNCG participated in a heterocomplex with Hsp90 and ERα in the absence of estrogen. However, SNCG dissociated from ERα after the cells were treated with E2. The binding pattern of SNCG to the unliganded ERα is same to that of Hsp90, which only binds to the unliganded ERα (Pratt and Toft, 1997). Similar to its binding pattern to ERα, SNCG also only bound to Hsp90 in the absence of estrogen. After cells were treated with E2, the liganded ERα dissociated from SNCG and Hsp90.

We next investigated if SNCG functionally stimulates ERα signaling. Transfection of SNCG gene into MCF-12A cells did not affect ERα expression (Figure 5c), which suggesting that overexpression of SNCG did not affect ERα expression levels. Transfection of SNCG significantly stimulated E2-mediated activation of ERα (Figure 5d). Treatment of wild-type and SNCG transfected MCF-12A cells with E2 resulted in a significantly differential increase in estrogen-responsive reporter ERE4-Luciferase (ERE4-Luc) activity relative to basal levels in untreated cells. Overexpression of SNCG gene in MCF-12A cells increased E2-stimulated reporter activity 5.2-fold over the SNCG-negative control cells. The SNCG-stimulated transcriptional activity of ERα was ligand-dependent, because SNCG had no significant effect on the transcriptional activity of ERα in the absence of E2.

Stimulation of ERα signaling in transgenic mammary gland

We next investigated the effect of SNCG on ERα signaling in mammary gland, which was measured by analysis of ERα-mediated transcriptional activity on E2-regulated genes of PS2 and Cathepsin D (Cat-D). Figure 6 shows a representative real time RT–PCR analysis of ERα, PS2 and Cat-D mRNA expression in three virgin control mice and three age-matched virgin transgenic mice. While basal levels of PS2 and Cat-D were detected in control mice, forced expression of SNCG in virgin mammary glands significantly enhanced PS2 and Cat-D expression, resulting in an average 3.4-fold (Figure 6b) and 4.8-fold (Figure 6c) increase over control mice, respectively. There was no significant change in ERα expression in control vs transgenic mice (Figure 6a), indicating that the increased PS2 and Cat-D expression in the transgenic mice is mediated by enhanced ERα signaling but not due to the alternation of ERα levels. To avoid the different in vivo estrogenic environments due to the different hormonal cycling of mice, we used whole mammary organ culture to study whether E2 can differentially regulate Cat-D expression in glands from control and transgenic mice. In this ex vivo model, the glands from virgin mice were cultured for 8 days to deplete the endogenous hormones before the E2 treatment. Expression of SNCG was clearly detectable in the glands from transgenic mouse in this short-term organ culture (Figure 7a). Consistent with the observed stimulation of Cat-D in the transgenic mice, expression of Cat-D was significantly increased in

**Figure 5** SNCG interacted with ERα and Hsp90 and stimulated ERα transcriptional activity in MCF-12A human mammary epithelial cells. (a–b) Interaction between SNCG and ERα and Hsp90. Cells were transiently transfected with pCI-SNCG or the control vector pCI-neo, and then selected with G418 as we previously described (Jiang et al., 2003). Association of SNCG with endogenous ERα and Hsp90 in the absence and presence of E2 was analysed by immunoprecipitation/Western blot. Total cell lysates were isolated from the cells cultured in the E2-free conditioned medium and in the medium containing 10 nM of E2. Equal amount of protein was subjected to IP with different antibodies. IP with anti-ERα (a) and anti-SNCG (b) followed by Western blot for ERα, SNCG and Hsp90. (c) Western analysis of ERα and SNCG in MCF-12A cells transfected with pCI-SNCG or the control vector pCI-neo. Expression of SNCG did not affect the ERα expression. SNCG stimulated ERα signaling in MCF-12A cells. (d) Stimulation of ER signaling. Cells were first transiently transfected with pCI-SNCG or the control vector pCI-neo. The transfected cells were selected with G418 and then transfected with pERE4-Luc as well as control reporter pRL-SV40-Luc. After transfection, cells were cultured in the ligand-free medium for 4 days as described in Materials and methods, treated with or without 1 nM E2 for 24 h before the promoter activities were determined by measuring the dual luciferase activity. The ERE reporter luciferase activity was normalized against the control renilla luciferase activity to correct for transfection efficiency. All values were presented as the fold induction over the control luciferase activity in the non-treated SNCG-negative cells, which was taken as 1. The numbers represent means±s.d. of three cultures.
E2 treated transgenic gland, resulting in a 5.4-fold increase over the E2 treated control gland (Figure 7b).

**Inhibition of SNCG-stimulated mammary gland proliferation by ERα antagonist and alteration of endogenous levels of estrogen**

As a chaperone protein participated in Hsp-based multichaperone complex, SNCG regulates (chaperoning) many pathways in growth and progression of cancer. To determine if SNCG-induced mammary gland proliferation is mediated by its chaperone activity on stimulation of ERα signaling, we studied the requirement of function of ERα and presence of E2 for SNCG-mediated effect on mammary gland proliferation. We analysed mammary proliferation and morphology by treatment of transgenic mice with tamoxifen and reducing endogenous levels of estrogen using ovariectomized mice. As expected, tamoxifen treatment and particularly ovariectomy reduced proliferation of mammary epithelial cells in control mice. Expression of SNCG in mammary gland significantly stimulated proliferation resulting in a 5.4-fold increase over control gland. Expression of SNCG was maintained during short-term organ culture, a quantitative RT-PCR analysis of Cat-D expression. Relative expression of mouse Cat-D gene in the mammary glands treated with E2 was calculated in comparison to that from control non-treated gland. The gene expression in the control non-treated gland was taken as 100% and regarded as control. All other values were expressed as a percentage of the control. The mouse beta actin gene was used as endogenous control. The numbers represent the means ± s.d. of duplicate RNA samples.

Figure 7 SNCG stimulated ERα transcriptional activity in mammary organ culture. A pair of inguinal mammary glands from a 14-week virgin control as well as transgenic mouse were isolated and cultured for 8 days in the E2 free mammary organ culture as described in Materials and methods. Glands were treated with or without 10 nM E2 for 24 h, protein and RNA were isolated. (a) A Western analysis of SNCG expression in combined control and transgenic glands from both non-treated and E2-treated gland. Expression of SNCG was maintained during short-term organ culture. (b) a quantitative RT-PCR analysis of Cat-D expression. Relative expression of mouse Cat-D gene in the mammary glands treated with E2 was calculated in comparison to that from control non-treated gland. The gene expression in the control non-treated gland was taken as 100% and regarded as control. All other values were presented as percentage over the control. The mouse beta actin gene was used as endogenous control. The numbers represent the means ± s.d. of duplicate samples.
Discussion

Synucleins are small proteins expressed predominately in neurons and have been specifically implicated in the neurodegenerative disorders such as AD and PD. However, SNCG was first identified and cloned as a breast cancer specific gene, which is highly expressed in advanced infiltrating breast carcinomas but not in normal or benign breast tissues (Ji et al., 1997; Wu et al., 2003). Aberrant expression of SNCG was also associated with ovary cancer progression (Lavedan et al., 1998; Bruening et al., 2000). The association between SNCG expression and the progression of steroid dependent cancers of breast and ovary suggest a potential role of SNCG in regulation of ERα.

Previously, we demonstrated an SNCG-stimulated ERα signaling in human breast cancer cell (Jiang et al., 2003). Functionally, SNCG significantly stimulates hormone-dependent growth of breast cancer cells both in vitro and in nude mice (Jiang et al., 2004). A notable finding in this study is that SNCG, acting as a chaperone protein participated in Hsp-based multiprotein chaperon complex for steroid receptors, induced extensive mammary gland proliferation, which is mediated by its stimulation of ligand-dependent transcriptional activity of ERα in mammary gland. Expression of SNCG in mammary gland in the virgin mouse greatly stimulated the proliferation of the mammary cells at end bud and resulted in a robust morphological branching, a phenotype similar to the pregnancy-induced proliferation. The identification of steroid

![Figure 8](image1.png)
Figure 8 Blocking of SNCG-stimulated proliferation of mammary cells by tamoxifen treatment and ovariectomy. Control and transgenic mice at 5-week old were implanted s.c. with 60-day slow-releasing tamoxifen pellet (5 mg/pellet, Innovative Research of America) or subjected to ovariectomy. After 8 weeks, both non-treated and treated mice were injected with BrdU, i.p. at a dosage of 75 mg/kg. The percentage of labeled nuclei is determined as described in Table 1. Numbers are means ± s.d. of three mice.

![Figure 9](image2.png)
Figure 9 Whole mount histological analysis of mammary gland. (a) Non-treated control mouse. (b) Non-treated transgenic mouse. (c) Ovariectomized transgenic mouse. (d) Tamoxifen-treated transgenic mouse. All mice were killed at 13-week old, the right inguinal gland was removed and subjected to whole mount gland fix, defat and staining.
receptors of ERz as molecular target for one of the actions of SNCG on the hormone-dependent growth of mammary gland suggest a critical role of SNCG on the pathogenesis of mammary tumors.

There are two distinct patterns of growth and development in mammary gland. The first involves the penetration of the mammary fat pad by branching ductal morphogenesis and the second involves the growth and expansion of mammary cells at the end bud and formation of differentiated lobule alveoli at the onset of pregnancy. While the ductal elongation is the normal mammary development before the onset of pregnancy, proliferation of end bud cells and formation of lobule alveoli is the consequence of functional multihormonal impact induced by pregnancy. In the transgenic gland, SNCG-stimulated robust proliferation of mammary epithelial cells at the end bud could be manifested by two different hormone-related mechanisms: stimulation of steroid hormone receptor signaling activity and local increase of estrogentic hormones or combination of both. In vitro studies using human breast cancer cells, we have demonstrated convincing data showing the chaperone activity of SNCG on stimulation of ERz transcriptional activity and E2-stimulated growth. As stimulation of ERz transcriptional activity by SNCG was also demonstrated in mammary gland, we believe that the same mechanism also applies to the normal mammary epithelial cells in the transgenic mouse model. In this regard, enhancement of ERz activity by SNCG will sensitize ERz response to estrogenic hormones and thus results in an enhanced hormonal environment and the induction of estrogen-mediated proliferation and mammary gland. Indeed, we demonstrated that inhibition of ERz function by tamoxifen or reducing endogenous levels of estrogen by using ovariectomized mice can completely blocked SNCG-induced gland proliferation, indicating the requirement of functional ERz. However, although we did not observe an increase in systematic levels of plasma estrogen in transgenic mouse vs control mouse (data not shown), it is possible that local intramammary levels of estrogen could be alternated. This becomes an increasingly important issue in an assessment of estrogen levels.

In Hsp-based chaperone complex, SNCG may also regulate other steroid hormone receptors besides ERz. We previously investigated the effect of SNCG on the transcriptional activity of ERβ. In contrast to the demonstrated stimulation of ERz signaling, SNCG did not stimulate the transactivation of ER-β (Jiang et al., 2004). However, since expression of SNCG in mammary gland stimulated a significant proliferation of end bud cells and a robust morphological branching, a phenotype resembles early pregnancy, steroid receptors involved in mammary expansion during pregnancy, such as PR, may also be a target for SNCG’s action for induction of highly proliferative status in virgin gland of the transgenic mouse. It is noteworthy although SNCG does not induce spontaneous mammary tumor in virgin mouse up to 12 month, it might induce tumors by multiple pregnancy due to the robust hormonal (estrogen and progesterone) stimulation at the onset of pregnancy.

Although mutations in SNCA have been detected in several cases of familial Parkinson’s disease (Polymeropoulos et al., 1997), the malignant phenotype in breast cancer is correlated with the high level expression of wild-type SNCG protein. Analysis of breast tumor samples did not identify any sequence variation of SNCG gene from its original neuronal environment and no gene amplification was detected either (Ninkina et al., 1998). Therefore, the aberrant expression of SNCG in breast carcinomas is caused by transcriptional activation of the gene. By analysing the promoter region of SNCG and conducting genomic sequencing, we demonstrated that the loss of methylation control in a CpG island located in exon 1 of SNCG was primarily responsible for its aberrant expression in human breast cancer (Lu et al., 2001; Gupta et al., 2003). The loss of epigenetic control of SNCG by demethylation was also demonstrated in ovarian cancers (Gupta et al., 2003). The most recent publication further indicated a universal loss of the epigenetic control of SNCG by demethylation of CpG sites within the CpG island of SNCG gene in a variety of different human carcinomas including liver, esophagus, color, gastric, lung, prostate and cervical (Liu et al., 2005). Since expression of SNCG gene is usually not detectable in normal neoplastic epithelial cells, its stage-specific expression in breast cancer strongly suggest that reactivation of SNCG by DNA demethylation is a common critical contributing factor for onset and malignant progression of breast cancer. We demonstrated here that expression of SNCG in mammary gland stimulates ER signaling and induces extensive mammary gland proliferation.

Our findings suggest that SNCG functions as a chaperone and participates in Hsp-based multiprotein chaperone system for efficient activation of ERz. It has previously been demonstrated in human breast cancer cells that the interaction between SNCG and ER-z stimulated cell growth in response to estrogen (Jiang et al., 2003). In addition, SNCG overexpression significantly stimulated the tumorigenesis of MCF-7 cells in response to estrogen, while it has no effect on tumor growth in the absence of estrogen. Consistent
with the requirement of E2 for SNC-stimulated tumor growth, we also demonstrated that SNC has no significant effect on tumor growth of ERα-negative MDA-MB-435 cells (Jia et al., 1999). These data clearly demonstrated a role of SNCG on stimulation of ligand-dependent ERα signaling in breast cancer cells and in normal mammary gland.

It is noteworthy that the role of SNCG in mammary carcinogenesis is also involved in non-ER-mediated functions. As a chaperone protein, SNCG regulates (chaperoning) many pathways in growth and progression of cancer. On the basis of our data and others, besides stimulation of steroid receptor signaling, SNCG has several major functions associated with tumorigenesis. First, SNCG is a candidate pro-metastatic mediator during breast cancer malignant progression. Expression of SNCG in breast cancer cells leads to a significant increase in motility and invasiveness in vitro and a profound augmentation of metastasis in nude mice (Jia et al., 1999). Consistent with the ability to confer metastatic potential to breast cancer cells, we recently demonstrated that patients with SNCG-positive breast cancer have statistically higher incidence for metastasis compared with patients with SNCG-negative cancer (Wu et al., 2006). In addition, a recent study also indicates a strong association between SNCG protein expression in primary tumors and distant metastasis in diversified cancer types, including liver, esophagus, colon, gastric, lung, prostate, cervical and breast cancer (Liu et al., 2005). Second, SNCG may contribute to tumorigenesis by promoting genetic instability. SNCG physically interacts with mitotic checkpoint protein BubR1 in breast cancer cells (Gupta et al., 2003). We demonstrated that SNCG expression in breast cancer cells overrides the mitotic checkpoint control and the inhibitory effects of SNC on mitotic checkpoint can be overthrown by enforced overexpression of BubR1 in SNCG-expressing cells (Inaba et al., 2005). These data suggest that SNCG expression compromises the mitotic checkpoint control by inhibition of the normal function of BubR1, thereby promoting genetic instability. Third, SNCG confers cellular resistance to induced apoptosis (Pan et al., 2002). SNCG expressing cells are significantly more resistant to the chemotherapeutic drugs compared with the SNCG-negative cells. In the present study, we demonstrated ERα as one of the critical target molecules for SNCG's action in normal mammary epithelial cells; turning normal mammary gland into a highly proliferative stage. Thus, aberrant expression of SNCG stimulates breast cancer development and progression, at least in part, by enhancing the transcriptional activity of ERα. The loss of epigenetic control by demethylation of SNCG gene can be used as a sensitive molecular tool in early detection in morphologically normal tissues before tumors emerge. Development of SNCG as a biomarker for breast cancer early diagnosis and progression warrants further investigation.

Materials and methods

DNA constructions and generation of transgenic mice

The MMTV regulatory sequences were derived from the plasmid pMMTV/MRG that previously used for MRG transgenic mice (Wang et al., 2003). The full-length SNCG cDNA sequence from pCI-SNCG (Jia et al., 1999) was subcloned into the BamHI and Apal sites of the MMTV plasmid. To ensure proper expression of this cDNA, SV40 splicing and polyadenylation signals were added to the 3’ portion of the construct. A 2.5 kb MMTV-SNC transgene was separated from the vector and isolated from an agarose gel. The DNA fragments were injected into fertilized eggs (5 ng/d) of FVB/N mouse. Injected cells were transferred into the oviduct of pseudopregnant ICR female mice and allowed to develop to term. At 6 weeks after microinjections of MMTV/SNC transgene, 30 newborn mice were generated and screened by Southern blot. Five transgenic mice were identified. Mating founder animals to wild-type (FVB/n background) male and female generated four first-generation transgenic lines. Transgenic males and females from the same family were mated to generate homozygous mice. If a mouse produced two or more litters of offspring that were transgenic, the mouse was considered to carry the transgene. Homozygous male and female mice from the same family were mated to each other to maintain the homozygous lines.

Whole mount histological analysis of mammary gland

Whole inguinal mammary glands were removed from virgin control as well as virgin transgenic mice. The removed gland was subjected to whole mount fix, defat and staining as previously described (Wang et al., 2003). Briefly, the inguinal mammary glands were fixed in 75% EtOH, 25% HoAC and stained with alum carmine (0.1% w/v). Whole mammary glands were destained in 70, 90 and 100% EtOH, respectively, defatted in xylene, and stored in methyl salicylate.

Mammary gland organ culture

A pair of whole inguinal mammary glands was removed from 14-week virgin female mice (FVB/n background) as previously described (Wang et al., 2000). The glands were cultured in phenol red-free medium 199 containing 5% charcoal-stripped FCS, with medium changed every 2 days. The medium was supplemented with following components from Clonetics: bovine pituitary extract (52 μg/ml), insulin (5 μg/ml), EGF (10 ng/ml) and hydrocortisone (1 μg/ml).

Gene transfection, immunoprecipitation and Western Blot

Gene transfection, immunoprecipitation and Western blot were conducted as we previously described (Jiang et al., 2003).

Assays for the transcriptional activity of ER-α

Cells were transiently transfected with a firefly luciferase reporter construct (pERE4-Luc) containing four copies of the estrogen response element (ERE). For the co-transfection experiments, the plasmid DNA ratio of pERE4-Luc to expression vectors of SNCG was 2:1. A renilla luciferase reporter, pRL-SV40-Luc, was used as an internal control for transfection efficiency. Luciferase activities in total cell lysate were measured using the Promega Dual Luciferase Assay System as previously described (Jiang et al., 2003). Absolute ERE promoter firefly luciferase activity was normalized against renilla luciferase activity to correct for transfection efficiency. Triplicate wells were assayed for each transfection condition and at least three independent transfection assays were performed.
Conditioned cell culture
Proliferating subconfluent MCF-12A human mammary epithelial cells were harvested and cultured in the phenol red-free IMEM containing 5% charcoal-stripped fetal calf serum for 3 days, and then in 1% charcoal-stripped FCS and phenol red-free IMEM for 1 day before addition of E2. Cells in the absence or presence of E2 were collected 24 h after addition of hormone and were subjected to the assays for ERα transcriptional activity.

Quantitative RT-PCR analyses
RNA was isolated and subjected to real-time PCR analysis using the TaqMan PCR core reagent kit (Applied Biosystems) and ABI Prism 7700 Sequence Detection System (Applied Biosystems). Data were analysed using Sequence Detection System (SDS) software version 1.6.3. Results were obtained as Ct (Threshold cycle) values. Gt is inversely proportional to the starting template copy number. Relative expressions of mouse PS2, ERα and Cat-D gene in the mammary glands from SNCG transgenic mice or the gland treated with E2 were calculated in comparison to that from control mouse using delta Ct method (User Bulletin #2, Applied Biosystems).

Abbreviations
AD, Alzheimer’s disease; BCSG1, breast cancer specific gene 1; Cat-D, Cathepsin D; ERα, estrogen receptor α; Hsp, heat shock protein; PD, Parkinson’s disease; PR, progesterone receptor; SNCA, α synuclein; SNCB, β synuclein; SNCG, γ synuclein.

Acknowledgements
This study was supported in part by grant (99-028-01-CCE) from American cancer Society, grants (W81XWH-04-1-0569) from the United States Army Medical Research and Development Command.

References


